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Abstract 
Cystinuria is a genetic disease leading a defective dibasic amino acid transporter 
in the renal proximal tubules resulting in an accumulation of urinary cystine. 
Urinary cystine precipitates into crystals which is believed to be a necessary step 
to stone formation. There is a wide variation in disease presentation that is not 
well understood and cannot be explained by either compliance with medical and 
dietary interventions, or differences in patient management. Predicting disease 
severity and managing patients expectantly is confounded by a paucity of 
validated methods to monitor disease activity and heterogeneity in how urinary 
dibasic amino acid levels are measured and reported in literature.  
 
Management of this disease is largely preventative and based on historical data. 
At Guy’s and St Thomas’, a clinic was set up to allow for a multidisciplinary 
approach to the management of these patients. It also provided a premise for 
research into patients with this disease. 
 
The objective of my research was threefold; to understand the factors that lead to 
severe disease, to investigate clinical markers of disease activity, and to 
understand the genetic mutations that cause the disease. 
 
This thesis is divided into seven chapters incorporating five supporting 
publications. Chapter one details what is already known on the subject. The 
evidence for dietary recommendations, current medical therapy and treatments 
are discussed. Chapter two describes the challenges to the clinician in the 
management of this disease. The basis of the specialist multidisciplinary clinic is 
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outlined, the roles of each team member and the geographic distribution of our 
patient cohort.  
 
Chapter three investigates the utility of dibasic amino acids in the management 
of cystinuria in particular, the association between urinary dibasic amino acids 
levels and stone formation. Dr Caroline Pardy and Dr Erin Mozley contributed 
significantly to this chapter. Spot urine samples were collected at the time of 
each clinic visit. The levels of the urinary dibasic amino acids and the association 
with stone formation as evaluated by ultrasound were analysed. There was a 
statistically significant association between the levels of urinary ornithine and the 
presence of stones seen on ultrasound scan. However, as current cystinuria 
medications aim at reducing cystine levels only with no known effects on levels 
of urinary ornithine, the prognostic value of this remains uncertain. 
 
Chapter four describes original research on the diagnostic value of crystalluria. 
Separate early morning and clinic urine were collected at each clinic visit and the 
association between presence of crystals and presence of stones and new stone 
growth were analysed. Malassez counting chamber and conventional cytospin 
methods were also compared. The results demonstrated that the presence of 
crystals in patients with cystinuria is associated with stone formation and new 
stone growth when based on clinic urine using cytospin method. This may serve 
as a useful adjunct rather than as a single diagnostic tool.  
 
For the first time, the genetic mutations found in a UK population are 
characterized and described in chapter five. Dr Rachael Mein contributed 
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significantly to this work. We found 23 new mutations in our UK population. We 
have found that in patients with mutations in SLC3A1, the presence of a 
missense mutation leads to lower levels of urinary lysine, ornithine and arginine. 
This is the first time such a genotype-phenotype association has been found and 
has the potential to improve our risk stratification of patients at the time of 
diagnosis and tailor their subsequent follow up. This association was not seen for 
cystine levels however there are limitations in current cystine assays that may 
account for this and is further discussed in the chapter.  
 
In chapter six, the use of protein modelling to model the two proteins encoded by 
SLC3A1 and SLC7A9 and the mutations that lead to protein dysfunction is 
described. The severity of the mutations in SLC7A9 as determined by the 
proximity of the mutation to the ligand binding sites and size of conformational 
change is shown to lead to a more severe biochemical phenotype as evidenced by 
raised levels of urinary dibasic amino acids. Further work in this area has the 
potential to lead to a personalized approach to the management of this disease. 
 
Finally, chapter seven summarises all the research findings, discusses the 
implications to current practice and future challenges in the management of these 
patients. 
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1 Introduction 
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1.1 Cystinuria is a genetic disease 
Cystinuria is an inherited dibasic aminoaciduria. A mutation in one of two genes 
SLC3A1 and/or SLC7A9 results in defective transport of urinary cystine and the 
dibasic amino acids across the small intestine and renal tubular membrane. In the 
kidneys, this results in an accumulation of urinary cystine, lysine, arginine and 
ornithine. As cystine is relatively insoluble compared to the other dibasic amino 
acids, high levels in urine can precipitate to form crystals and eventually stones 
and lead to stone-related complications3.  
 
The clinical presentation is varied; ranging from some patients having stone 
episodes every few months to other patients having only one stone in their 
lifetime. A large stone burden may result in chronic kidney disease and even 
nephrectomy5-7. Cystinuria represents 1% of adult and 6–8% of paediatric stone 
disease, although the prevalence varies between populations8. The prevalence of 
cystinuria is likely to be underestimated in many studies because patients with 
mild disease may never present with stone disease or are not screened for 
cystinuria.  
 
The recurrence rate of stone episodes is reported to be 60%.9 Men have been 
reported to have more severe disease than women and form stones more 
frequently.10 Reports in the literature suggest that three-quarters of patients with 
cystinuria develop bilateral stones;11 however, in our own cohort, we have found 
only one third of patients with bilateral disease.  
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Figure 1.1 The first cystine stone as described by Wollaston in 1810. (Courtesy of the 
Gordon Museum, Guys Campus Kings College London) 
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Total Number of patients 86 
  
Male: Female 1.32 
Average age of presentation  23 
Number of patients with a delayed diagnosis of Cystinuria 23 
Average delay in diagnosis (years) 7.8 
Passes stones spontaneously 46 
Bilateral stones 26 
Radio opaque stones  16/30 
Respond to ESWL  15/32 
Hypertensive  28 
New diagnosis of hypertension from clinic 22 
Table 1.1 Patient Demographics from the Guys and St Thomas’ Cystinuria Clinic. Out of 
30 patients who have undergone X-ray imaging, just over half (N=16) have stones that are 
radio-opaque. Therefore, we use ultrasound as our preferred mode of imaging to detect 
cystine stones. Furthermore, only 15 out of 32 patients respond to ESWL treatment of their 
stones. We routinely offer ESWL treatment to these patients who have been known to 
respond in the past. Patients who fail ESWL treatment are generally offered more invasive 
treatment i.e. URS/PCNL. 
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1.1.1 Diagnosis 
The initial diagnosis of cystinuria is made by stone analysis showing cystine 
composition and raised levels of urinary dibasic amino acids. Commonly, 
sodium cyanide-nitroprusside is used as a screening test and only requires a urine 
sample. Cyanide reduces cystine to cysteine which then binds to nitroprusside 
resulting in a red to purple colour change12. The sensitivity of the test has been 
reported to be 72% with a specificity of 95%.12  
 
As it is a rare disease, patients often present several times with stone disease 
before a diagnosis is made. In our experience, from our own cohort of patients 
who have been referred to our specialist clinic, the average delay in diagnosis 
was 7.8 years3.  
 
Recent evidence suggests that hypertension occurs more frequently in patients 
with cystinuria than the general population and therefore these patients should be 
routinely screened6. We have also found in our patients 28/86 are hypertensive 
and have diagnosed a further 26% (22/86) patients with hypertension requiring 
treatment3. 
 
1.1.2 Genetics 
Mutations in SLC3A1 and/or SLC7A9 explain the majority of cases of 
Cystinuria. SLC3A1 encodes for the neutral and basic amino acid transport 
protein (rBAT) and SLC7A9 encodes for the light chain b amino acid transporter 
b(0+)AT 13,14. The proteins form a dimer linked by a disulphide bridge 15. 
b(0+)AT consists of 487 amino acids (53481 Da) with 12 transmembrane helices 
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that form the channel through which dibasic amino acids (cystine, lysine, 
arginine and ornithine) are transported into the cell with the exchange of neutral 
amino acids. rBAT is the larger of the two subunits consisting of 685 amino 
acids (78852 Da), with a single transmembrane helix and a large extracellular 
domain. Experimental studies suggest that rBAT may function as an activator of 
b(0+)AT 14,16.  
 
SLC3A1 mutations are inherited in an autosomal recessive pattern whilst 
mutations in SLC7A9 can be regarded as inherited in an autosomal dominant 
pattern with incomplete penetrance 17. In SLC3A1, mutations in both alleles of 
the gene are required for disease presentation. In SLC7A9, mutations in both 
alleles can result in cystinuria however patients with only one mutated allele can 
also form cystine stones10.  
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Figure 1.2 Difference in inheritance pattern of SLC3A1 and SLC7A9. In SLC3A1, an 
inherited mutated allele from both the mother and father is required for an offspring to 
have cystinuria. If only one mutated allele is inherited, the offspring will have normal 
cystine levels. In SLC7A9, again, if two mutated alleles are inherited, one from each parent, 
the offspring will have cystinuria. However, offspring with one mutated allele from one 
parent may also have higher than normal levels of urinary cystine. These offspring may 
present with cystine stones.  
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1.2 Current Medical Therapy and Treatments  
1.2.1 Preventing stone formation 
Preventing stone formation is an important focus for clinicians undertaking 
specialist long-term cystinuria management and care. The urologist’s aim is to 
minimize the frequency of renal colic episodes, the need for urological 
interventions and the adverse sequelae of recurrent stone formation.  
 
The ratio of soluble to insoluble cystine is affected by its urinary concentration, 
urinary pH, and urine volume18. Cystinuria is more likely to lead to long-term 
renal damage than other stone diseases19,20and, therefore, our clinic has 
employed a multidisciplinary approach to managing these patients.  
 
1.2.2 Hydration 
Adequate hydration is the simplest and most important method to prevent stone 
formation in cystinuria. Reducing cystine concentration in urine can be achieved 
by hyperdiuresis. If patients with cystinuria excrete up to 1400 mg of cystine per 
day and the solubility of cystine is approximately 300 mg/l at pH 7.0, then a 
urine output of 5 l per day should enable the total clearance of cystine.21 
However, this level of fluid intake is not a sustainable for most patients and a 
target of exceeding 3 l per day is more realistic22,23.  Specific regimens might 
also be recommended, often involving waking at night to drink a specified 
volume of fluid.21,22,24 Traditionally, night was thought to be when most patient 
were at highest risk of cystine supersaturation.25 However, studies have not 
shown a diurnal difference in the number of discrete supersaturation episodes.26 
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We ask our patients to complete a diary describing fluid intake and our specialist 
dietician provides tailored advice regarding fluid management depending on 
patient’s individual circumstances.24 Other researchers have found that patients 
struggle to maintain a high fluid intake, but improved with frequent monitoring 
and feedback during 6-monthly clinics.27 In our own experience, the frequency of 
follow up is varied depending on patient need and response. 58% of our patients 
have increased their fluid intake since attending our clinic; 66% of our patients 
are maintaining a fluid intake of greater than 3 l per day and 13% 4 l and above1. 
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Figure 1.3 Diagram of the Guys diet clinic model (adapted from Wong et al 20121) 
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Alkalizing beverages, such as mineral water, which is rich in bicarbonate and 
low in sodium (1500 mg bicarbonate per l, maximum 500 mg sodium per l) and 
citrus juice are the preferred fluid sources.21 There is also evidence suggesting 
that orange juice is more effective than lemonade in alkalinising urine and 
promoting hypercitraturia28. The authors of this paper concluded this may be 
protective in recurrent calcium oxalate and uric stone formers and could be 
encouraged particularly for patients who are intolerant to potassium citrate. 
Potentially, the alkalinising effect of orange juice may also be beneficial in 
cystinuria patients although this has not been tested. To maintain high fluid 
intake, patients should be advised to drink what they like, provided it mostly 
consists of a clear fluid, and to avoid caffeinated drinks.21 
1.2.3 Diet 
The recommended diet for cystinuria patients includes maintaining a healthy 
weight, limiting intake of salt and animal protein, and increasing vegetable 
protein (as a substitute for animal protein), fruit and vegetables22,23,29-35.   
 
Historically, the ability of patients to adhere to and maintain specific dietary 
regimens has been questioned23. However, in our multidisciplinary practice, with 
regular dietetic input and support, patients have made positive changes to their 
diets.  
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Figure 1.4 Recommended dietary changes for a patient with cystinuria 
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Figure 1.5 Number of patients making positive changes to their diet after review (Adapted 
from Wong et al 20121) 
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Urinary pH is also inversely related to body weight,36 overweight patients, 
therefore, have a less favourable urine pH, which is conducive to stone 
formation. 30% of patients in our cohort, when first seen in clinic, were 
overweight (defined as a BMI 25.1–30 kg/m2) and 28% were clinically obese 
(BMI >30kg/m2). With the regular dietetic support, 12.5% of patients in the 
overweight group and 34.8% of patients in the obese group have lost weight.  
 
Decreased total sodium intake can reduce the amount of cystine excreted in the 
urine.25,31,37 Lowering sodium intake by 3.5 g per day decreases cystine excretion 
by 156 mg per day, and encourages cystine solubility.32  
 
In the UK, the average salt intake per day is 8.6 g (3.4 g sodium), 75% of this 
salt intake comes from processed foods. Patients are encouraged to restrict their 
salt intake to ≤6 g per day (2.5g of sodium)38,39. Patients are advised to eat more 
fresh foods, to check food labels in order to choose the lower salt options and 
stop adding salt to their food, instead experimenting with alternative seasonings. 
68% of patients have reduced their salt intake since attending our clinic.  
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Figure 1.6 Methionine, an essential amino acid found in many food groups such as egg, 
nuts, fish and meat is a cystine precursor (adapted from Wikipedia.org) 
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Reducing animal protein intake also decreases cystine excretion by reducing 
methionine and cystine intake.33 A reduced methionine—a cystine precursor—
diet has been recommended for patients with cystinuria. In one case study, a 
patient who followed a strict low methionine diet for 10 years found that his 
cystinuria effectively disappeared.40 Moreover, an extremely low protein diet (20 
g per day) was found to reduce urinary cystine excretion by 34%.22,41 However, 
this level of protein restriction is not advisable, and may even be harmful to 
patients42,43.  
 
In our clinic, a stones diet-based guideline is used to help patients achieve a 
restricted animal protein intake.44 Patients are advised to limit their intake of 
protein from animal sources to 60% of their total protein requirements, the 
remaining 40% should come from vegetable protein foods and other sources (for 
example, the small amounts of protein in rice or bread). A patient’s daily protein 
intake is estimated from their diet history and compared with their protein 
requirements calculated using the Elia equation (6.25(0.17g/kg body weight/day, 
adjusted for obese patients with BMI >30)45.  A cookbook with vegetable 
protein-based recipes and specific advice for patients with cystinuria was 
produced by our team.2 
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Figure 1.7 Thomas et al. Lose a Stone Cystinuria cookbook2 
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Following dietary advice, 68% of our patients decreased their animal protein 
intake and 62% increased their vegetable protein intake. We carefully monitored 
those patients who decreased their animal protein intake, and without a 
concurrent increase in vegetable protein, to ensure they consumed enough 
protein. To determine if a patient was malnourished, we assess grip strength 
using a dynamometer—a reduction in grip strength indicates protein 
malnutrition. Decreasing animal protein intake also increases urinary pH, which 
will help limit cystinuria29, as can increased fruit and vegetable intake owing to 
the high levels of potential basic amino acids in fruits and vegetables.34 In our 
clinic, 72% of patients increased their fruit and vegetable intake following 
dietary advice.  
 
Patients with cystinuria are at risk of forming calcium phosphate stones,46 and 
low calcium diets are known to increase the risk of forming stones.47 To ensure 
that patients with cystinuria receive enough dietary calcium they are advised that 
at least two sources of protein come from dairy foods.  
 
Dietary changes can reduce levels of cystine in the urine, and some of our 
patients with cystinuria have had notable success with reducing stone episodes.33 
However, no randomized studies have been conducted to demonstrate that 
dietary changes reduce stone episodes.  
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1.2.4 Medical Management 
Medical therapy for cystinuria is focused on lowering the urinary concentration 
of cystine and increasing its solubility.48 Aggressive medical management can 
reduce the incidence of stone formation by 78%.48  
 
Cystine precipitates into crystals in acidic urine (pH 5–7)18 In patients with 
consistently low urinary pH despite dietary changes and weight loss, an 
alkalinizing agent can be used. Potassium citrate or sodium bicarbonate can 
increase urinary pH and the solubility of cystine.9 However, in our clinic we 
prefer to use potassium citrate, which avoids the excess urinary sodium load that 
arises from bicarbonate therapy and thereby might lead to mixed composite 
stones.  27 of patients in our cohort receive potassium citrate compared with just 
3 on sodium bicarbonate. Patient compliance with potassium citrate is limited 
due to its poor taste, but can be overcome by using a tablet form (Urocit K©), 
which unfortunately in the UK is more expensive and difficult to obtain. All 
patients receiving potassium citrate should have their serum potassium levels and 
urinary pH checked regularly aiming for a urinary pH of 7–7.5. In our clinic, we 
provide urine dipsticks and ask all our patients to complete a urinary pH/fluid 
diary. Excessive alkalinisation of urine to a value consistently >pH 7.5 can 
predispose patients to calcium phosphate stone formation, which has happened to 
two of our patients.  
 
In addition to alkalinisation therapy, thiol-binding drugs such as D-penicillamine 
and α-mercaptopropionylglycine (also known as tiopronin)9,23 can be used to 
treat cystinuria. 30% of our patients are on thiol-binding medications which work 
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by reducing cystine to two cysteine molecules. A soluble drug-product 50 times 
more soluble than cystine is formed, which can then be excreted in urine. In vitro 
studies suggest that alkalinisation of urine might also potentiate the effect of 
these thiol drugs.49 Tiopronin is reported to have fewer side effects than D-
penicillamine (75.5% vs 83.7%),50 leading to improved patient experience and 
compliance. Side effects include non-specific allergy, nausea, leucopenia, 
thrombocytopaenia, proteinuria and Systemic Lupus Erythematosus-like 
syndromes, so patients should be regularly monitored48. 9% of our patients have 
stopped D-penicillamine and 6% tiopronin due to problems of tolerability. Due 
to the potential side effects, all patients receiving D-penicillamine and tiopronin 
have 3–6 monthly full blood count, liver function tests, albumin, renal function, 
vitamin B6 and urine dipstick for protein levels checked. Due to the risk of 
vitamin B6 deficiency in patients taking D-penicillamine only, vitamin B6 
supplements are also recommended.  
 
Captopril is an angiotensin–converting–enzyme inhibitor, more commonly used 
to control blood pressure and its clinical efficacy in the context of cystinuria is 
debatable.51,52 It works by forming a thiol-cysteine mixed disulphide complex, 
which is more soluble than cystine. In patients with hypertension, captopril can 
be used as an alternative or adjunct treatment. In our clinic four patients with 
cystinuria are on captopril.  
  
 44 
 
 
 
Figure 1.8 The number of patients on drugs in our specialist cystinuria clinic (Thomas, 
Wong et al 20143) 
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1.2.5 Surgical Management 
The surgical techniques for removal of cystine stones are identical to all other 
stone types. The choice of intervention will depend on numerous factors, such as 
stone size, location, nature of previous interventions, availability of equipment, 
surgeon and patient preference. Patients with cystinuria have high recurrence 
rates and therefore surgical planning lies in achieving a balance between the 
safety of the procedure and stone clearance.21 
 
Like all patients who form stones, a substantial proportion of those with 
cystinuria can spontaneously pass stones before their size becomes problematic. 
In our cohort, >50% of patients pass stones spontaneously. Those patients who 
develop recurrent stones will often know from previous experience the maximum 
size of stone that they are likely pass, smaller asymptomatic stones can, 
therefore, be monitored. However, prompt treatment is required if stones fail to 
pass, after developing colic or if the stone grows.  Some evidence indicates that 
complete stone clearance leads to a longer stone-free period.53 
1.2.5.1 Extracorporeal shockwave lithotripsy  
Extracorporeal shockwave lithotripsy (SWL) is the non-invasive fragmentation 
of stones into smaller fragments that are more likely to pass. Cystinuria stones 
are widely believed to be resistant to fragmentation by SWL, which is supported 
by clinical and in-vitro studies, although the results have varied. For example, in 
one study 8 of 10 patients with cystinuria and ureteric stones were stone free 
after two sessions of lithotripsy, leading the researchers to recommend that 
ESWL be considered the first line of treatment for all ureteric stones.54 However, 
other researchers have demonstrated in a paediatric population that stone 
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fragmentation was inferior in patients with cystinuria and in stones larger than 
11mm.55 In our own experience, 47% (15/32) of patients have stones that 
respond to ESWL and we consider it a useful first line treatment for those stones 
<1cm in patients who have previously had successful ESWL treatment.  
 
In vivo studies have shown that significantly more lithotripsy shockwaves may 
be required to fragment cystine stones compared with other stone types.56 There 
is also some evidence to suggest that cystine stones with a rough external surface 
on plain imaging are more amenable to shockwave energy than those with a 
smooth surface.57 Furthermore, rough stones tend to have a lower attenuation 
coefficient than smooth ones on computerised tomography suggesting that 
computed tomography might aid the identification of stones suitable for ESWL.57  
1.2.5.2 Ureterorenoscopy 
Rigid ureteroscopy or flexible ureterorenoscopy (also known as retrograde 
intrarenal surgery) is a suitable treatment modality for the majority of ureteric 
and pelvicalyceal stones less than 2cm.21,58 Ureteroscopic surgery is minimally 
invasive and confers low morbidity with a short hospital stay, a major advantage 
and of particular importance for patients with cystinuria, who often undergoing 
multiple procedures, possibly in the context of having established CKD or a 
single kidney. The holmium laser can fragment even the hardest stone and many 
stone surgeons advocate it as the ideal energy source for ureteroscopic surgery59.  
1.2.5.3 Percutaneous nephrolithotomy 
Percutaneous nephrolithotomy (PCNL) might be required for large or complex 
stones that are not amenable to ESWL or retrograde intrarenal surgery. The 
threshold for deciding to use PCNL in patients with cystinuria might be higher 
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than in other stone formers due to the recurrent nature of cystine stone formation 
and a desire to balance the need for repeated interventions with the risk of 
complications over a lifetime. PCNL access techniques and sheath size vary but 
all allow large fragments to be removed and offer a high chance of complete 
stone clearance23. Historically, retreatment rates following PCNL are higher for 
cystinuria stones than for other stone compositions (50% versus 15%).60 Indeed, 
59% (48/82 out of data available in our cohort) of our patients have previously 
had a PCNL, therefore, the risks associated with PCNL and the potential renal 
damage should be considered when planning surgery and the number of PCNL 
procedures minimised. Our own preference is to use more minimally invasive 
approaches whenever possible.  
 
A particularly challenging situation arises when patients with cystinuria and a 
solitary kidney require PCNL. In the CROES study, stone clearance was inferior 
in patients with single kidneys, who also had poorer post-operative renal 
function61. However, in our experience, stone clearance and complication rates 
were acceptable, with a stone clearance rate of 77% and either an improvement 
or stabilization in renal function at three months62.  
1.2.5.4 Percutaneous chemolysis 
Historically, some patients with cystinuria have been treated with 
chemodissolution agents, such as N-acetyl cysteine with bicarbonate, 
administered by percutaneous irrigation via a nephrostomy tube but with limited 
success.21,63 Concomitant advances in retrograde intrarenal surgery, PCNL and 
medical prevention have rendered this technique largely obsolete. 
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1.2.5.5 Open surgery 
Advances in minimally invasive stone surgery have almost entirely obviated the 
need for open surgery in the UK, which is only considered in rare circumstances 
where minimally invasive approaches have failed or are contraindicated.21 
Interestingly, 22% of patients in our clinic have had a history of prior open 
surgery, usually in their childhood or when the disease first presented. This may 
reflect the number of patients who had a delayed diagnosis at initial presentation 
and had large volume stone disease. Comparative data on the proportion of 
cystinuria patients having previously undergone open surgery are not readily 
available. A history of previous open surgery be reflected in complex anatomy 
and can make future endourological surgery more challenging, though specific 
data addressing this issue is lacking.  
 
1.3 Conclusion 
Cystinuria is a challenging disease; it affects predominantly a young population 
and the diagnosis is often delayed as patients present with stone-related 
complications several times before the possibility of cystinuria is even 
considered. These patients are more susceptible to stone-related morbidity and 
chronic renal impairment. 
 
The aims of management of the disease are threefold; firstly to lower urinary 
cystine levels and increase its solubility through dietary measures and medical 
therapy. Secondly, to reduced the morbidity associated with stone disease. 
Finally to minimize irreversible renal dysfunction caused by nephron loss. At 
Guys and St. Thomas’, we adopt a multidisciplinary approach. Patients attend 
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regular follow up led by a consultant urologist with a specialist interest in stone 
disease, supported by a renal physician, dietician, uroradiologist and dedicated 
stone specialist nurses. 
 
There is a wide variation in disease presentation that is not well understood and 
cannot be explained by either compliance with medical and dietary interventions, 
or differences in patient management. Predicting disease severity and managing 
patients expectantly is confounded by a paucity of validated methods to monitor 
disease activity and heterogeneity in how urinary dibasic amino acid levels are 
measured and reported in the literature. Furthermore, there are over 200 genetic 
mutations that have been described in literature, with poor correlation to the 
clinical phenotype. The genetic mutations in a UK population have not been 
previously characterised.  
 
The objective of my research was threefold; to understand the factors that lead to 
severe disease, to investigate clinical markers of disease activity, and to 
understand the genetic mutations that cause the disease. I characterised the 
clinical phenotype of patients with cystinuria by prospectively collecting patient 
data from patients attending our specialist clinic. I also prospectively collected 
urine samples in clinic (early morning urine and clinic urine samples) for 
measurement of urinary dibasic amino acids levels and crystals. I investigated 
the utility of the dibasic amino acid levels and urinary crystals as clinical markers 
for disease activity by investigating the correlation between urinary dibasic 
amino acid levels, urinary crystals and clinical phenotype. Robust clinical 
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markers will be instrumental in measuring the severity of patient disease and 
efficacy of patient management. 
 
I also characterised the genetic mutations that cause cystinuria in a UK 
population and investigated associations between genotype and clinical 
phenotype. I used computational protein modelling to explore the mechanisms 
underlying the genotype-phenotype associations. I believe a better understanding 
of genetics and how it influences clinical phenotype will result in a better 
understanding of the differences in disease presentation in patients. This will lead 
to improvements in management which can be tailored to the individual 
genotypic needs.  
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2 Challenges in managing 
patients with Cystinuria 
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2.1 Introduction  
 
Due to a dysfunctional protein transporter of the dibasic amino acids, cystinuria 
patients are at risk of forming cystine stones. The clinical presentation varies; 
some patients will pass occasional stones and others will present frequently with 
colic requiring hospital admission, medical or surgical intervention. Patients with 
‘severe’ disease are at significant risk of renal loss. The aims of follow up of 
patients with this condition are preventative and pre-emptive intervention on 
growing stones before they can cause colic and other stone-related 
complications.  
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Figure 2.1 Estimated Glomerular Filtration Rate of our cystinuria cohort as measured by 
the Modification of Diet in Renal Disease equation adjusted for age and gender of patient. 
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The underlying pathophysiology of why some patients have clinically mild 
disease and others have more severe forms requiring frequent surgical 
intervention is unclear. It is not understood what triggers the disease to present 
and currently no guidelines on how patients should be monitored once they are 
diagnosed. Often, whether a patient has mild or severe disease is not clear until 
the patient has been observed for a number of years. Research in this condition 
however, is hampered by several factors; firstly, as a rare disease, patient 
numbers are few and most urologists may only see one or two cases of cystinuria 
in their lifetime. Secondly, we interfere with the natural history disease by 
preventative measures, pre-emptive management and treatment. Finally, there is 
currently no validated method to measure disease activity. The focus of my 
research is therefore to understand the factors that lead to disease, to investigate 
the markers of disease activity, and to understand the genetic mutations that 
cause cystinuria and how they might correlate with phenotype. 
 
2.2 Specialist Multidisciplinary Cystinuria Clinic 
 
The Guys and St Thomas’ Hospital specialist Cystinuria clinic was established in 
August 2008 by a Consultant Endourologist (KT). Patients have a joint review 
with a Consultant Urology and Consultant Nephrologist, undergo an ultrasound 
scan by a specialist Uroradiologist and specialised review by a dietician. The 
optimum follow up schedule is unknown and unique and tailored to each patient. 
They are seen regularly from three monthly to annually depending on the 
severity of their disease. The frequency of follow up is dictated by the severity of 
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the individual patient’s condition with a threefold aim; stone prevention, to 
capture new stone growth and intervene to prevent stone-related complications.  
 
Figure 2.2 Map of the UK patients who attend our specialist clinic 
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At each clinic visit, patients bring in an early morning urine sample and a clinic 
sample for spot measurement of urinary dibasic amino acids and crystalluria. In 
particular, attention to hypertension, hypercholesterolaemia and diabetes mellitus 
are undertaken to optimize long-term renal function6. Patients are encouraged to 
take control of their disease and to do as much home monitoring as possible with 
regard to fluids, pH, diet, weight loss and blood pressure. Renal function and 
other blood tests are monitored regularly particularly for patients on thiol-
binding drugs. Patients are consulted during their review as to whether they have 
had any stone episodes since their last visit. A stone episode is defined as the 
spontaneous passage of stones, an episode of acute colic with or without hospital 
attendance, or clinically significant stones that require intervention including 
ESWL, URS and PCNL. When choosing what intervention is required, patient 
factors are also taken into account; one may want to avoid an operation in a 
patient who has multiple comorbidities and may be at high risk for a general 
anaesthetic and attempt ESWL if appropriate, bypassing the need for a general 
anaesthetic in the first instance.  
 
In practice, the frequency of follow up is heavily influenced by a patient’s initial 
presentation, until sufficient time has passed and the individual’s disease course 
becomes clearer. For example, a patient whose stone disease is dormant for 
several years and presents with large bilateral staghorn calculi would be 
considered to have a severe clinical phenotype and may be followed up more 
closely than a patient who presents initially with a single renal stone <1cm. 
Patients who present younger are also considered to have more severe disease 
than those who present at an older age in keeping with what we know of cystine 
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supersaturation64. The practice of more frequent follow-up of more clinically 
severe patients and less frequent follow up in patients perceived to have a milder 
form of cystinuria creates a clinician-led selection bias. Furthermore, we try to 
balance the frequency of follow up against the disruption to patient’s lives as 
many of our patients travel long distances to attend the clinic.  
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Figure 2.3 Age at presentation of patients with Cystinuria in our cohort (Adapted from 
Thomas, Wong et al 2014) 
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As we are screening siblings of patients who already have a diagnosis of 
cystinuria, we are building a unique cohort of people who have cystinuria 
mutations who at the point of diagnosis may be stone-free. We have the 
opportunity to monitor these people and learn about the natural course of the 
disease before these people even present with stone disease.  
 
All patients attending clinic are invited to participate in our genetics study and 
consent to a peripheral blood sample taken for DNA sequencing and multi-ligand 
dependent probe amplification.  
 
One of the main challenges in clinical research in cystinuria is that there is 
currently no validated measurement of disease severity. Given the high 
frequency of which some patients’ experience stone episodes, patients recall of 
stone episodes can be unreliable. In addition, any clinical intervention including 
dietary or medical therapy can potentially alter the natural progression of the 
disease48. Furthermore, there is a recognisable bias with more frequent follow up 
of patients with more frequent stone episodes or a larger stone burden.  
 
A predictive clinical marker of stone growth and burden would therefore be 
particularly useful in the long-term management of patients with cystinuria. An 
optimal follow-up regimen could then be tailored to the disease burden of 
individual patients, ensuring that review is frequent enough not to miss 
significant stone formation, allowing pre-emptive intervention if necessary to 
prevent stone related complications. No such marker currently exists.  
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2.3 The utility of dibasic amino acids  
Cystinuria is caused by an accumulation of urinary cystine. Traditionally, 
measurements of urinary cystine were taken over a 24-hour period. Normal 
urinary cystine level is between 0-100umol/g creatinine in 24 hours9. Collection 
of 24-hour urine is cumbersome for patients particularly when they are traveling 
long distances to the clinic. Although 24-hour urinary cystine is useful 
diagnostically, it has not been shown whether it has any prognostic value. In our 
laboratory, we use ‘spot urine’ measurements, a validated and pragmatic 
approach to monitoring. Studies on the biochemical composition of spot urine 
demonstrates that it can accurately reflect 24 hour urine collection65 however its 
use as a marker of disease activity has not previously been tested.  
 
However, standard hospital laboratory assays measure urinary free cystine which 
does not account for the insoluble cystine present in crystal form. Furthermore, 
current assays do not distinguish between free cystine and cystine bound to thiol-
containing drug complexes as used in the treatment of cystinuria. Therefore, the 
measured urinary cystine level is not a true reflection of total cystine. Coe et al 
have described a solid-phase assay to measure urinary cystine supersaturation 
and cystine capacity and have found this method to be reliable but it is currently 
not widely available limiting its use37,64. Using this technique, patients who 
present at an older age exhibit a lower cystine supersaturation level than younger 
patients suggesting an age protective effect.65,66  
 
I examined the association between free urinary cystine measurement and 
patient’s stone episodes. Furthermore, the clinical utility of other dibasic amino 
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acids (lysine, arginine and ornithine) which are also raised in cystinuria has not 
previously been investigated. As urinary cystine measurements are not a 
reflection of true levels, we hypothesized the measurement of the other dibasic 
amino acids may clinically be more useful. 
 
2.4 The prognostic value of urinary crystals 
Crystalluria is a necessary step in cystine stone formation. Daudon et al have 
previously shown in other types of stone disease, the presence of urinary crystals 
is predictive of stone recurrence67. We hypothesize the measurement of urinary 
crystals in cystinuria may be useful clinically to predict stone episodes and can 
be used as a biomarker to determine stone formation.  
 
We ask patients for a clinic urine and early morning urine sample with each 
clinic visit. Early morning urine has traditionally believed to be most reflective 
as it is the most concentrated urine collected in a 24-hour period due to overnight 
accumulation of crystals. We compared the utility of both early morning urine 
samples with a mid-morning clinic urine sample.  
 
Prior studies on urinary crystalluria have used the Malassez counting 
chamber67,68. We compared the utility of the Malassez counting chamber with 
conventional cytospin methods which could potentially be automated.   
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2.5 Genetics 
Historically, the classification of cystinuria was based on parental urinary 
phenotype. Type I is autosomal recessive; these patients have parents who are 
carriers, each with one mutated and one normal allele. The parents excrete 
normal amounts urinary cystine. Type II and III have parents who have varying 
levels of dibasic amino acids. In type II, parents excrete >900umol/g of 
creatinine, type III parents excrete 100-900umol/g of creatinine. Type II and III 
cystinuria are therefore regarded as autosomal dominant with incomplete 
penetrance. Advances in molecular genetics have led to greater understanding of 
the underlying mutations that cause cystinuria. The old classification has been 
superseded by a newer classification where type A refers to all patients with 
SLC3A1 mutations which confer a type I phenotype. Type B refers to patients 
with SLC7A9 mutations which cause all three phenotypes. Type AB are patients 
with mutations in both34.  
 
Over 200 genetic mutations have been described in cystinuria worldwide. The 
mutations are diverse in both SLC3A1 and SLC7A9. 50% of patients with type 
A cystinuria will present with stone disease in their first decade of life and 
another 25% in their teenage years34. Genotype-phenotype studies have been 
done showing no difference in clinical presentation between type A and type B 
disease 10.  
 
My thesis describes one of the first studies which look at mutations specific to a 
UK population. I characterised the genetic mutations that cause cystinuria and 
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investigated associations between genotype and clinical phenotype, using protein 
modelling to explore the underlying mechanisms. 
 64 
3 The Utility of Dibasic Amino 
Acids 
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3.1 Introduction 
 
Spot measurements of urinary cystine have been shown to accurately reflect 24-
hour urine excretion, as described in chapter 2. Spot urinary cystine has been 
useful diagnostically but its prognostic value has yet to be determined. At the 
Guys and St Thomas’ specialist cystinuria clinic, we collected spot urine at each 
patient clinic visit for analysis. I was interested in investigating the clinical utility 
of measuring urinary cystine as well as the other dibasic amino acids (lysine, 
arginine and ornithine). 
 
There are various methods in which free unbound urinary cystine can be 
analysed including the use of cyanide-nitroprusside and spectrophotometry, 
Liquid Chromatography-tandem Mass Spectrometry (LC-MS), and High 
Performance Liquid Chromatography (HPLC). Not all techniques however are 
widely available in a hospital laboratory for diagnostic use69. Our laboratory uses 
ion-exchange HPLC with post-column ninhydrin complex formation and 
detection of the coloured compound produced at 570nm. The expected free 
urinary cystine in a patient without disease is in the range of 4-15umol/mmol Cr. 
In a patient with cystinuria, urine concentration reach levels of around 
300umol/mmol Cr.  
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Figure 3.1 Figure showing a biochrom chromotogram of a cystinuria patient on 
penicillamine (Adapted from Mozley et al). Note a penicillamine –cysteine peak can also be 
seen.  
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This Biochrom technique however requires acidification of urine samples for 
analysis to a pH <2 which potentially can alter the solubility of cystine in the 
sample18,70,71. Dolin et al described a technique that involves alkalinisation of 
urinary samples with sodium bicarbonate to a pH >9 to ensure all the cystine in 
the sample is solubilised72.  
 
We performed a small study in collaboration with the University of Southampton 
on 14 patients to assess the method of cystine quantification by comparing our 
Biochrom technique with the Biochrom at the University of Southampton in 
addition to an internally validated LC-MS method. I prepared the samples for 
analysis under the guidance of Dr Charles Turner. Dr Erin Mozley performed the 
sample analysis through the Biochrom and LCMS. We performed a sub-group 
analysis comparing alkalinised samples using a modified Dolin technique and 
non-alkalinised samples using both methods.  
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Figure 3.2 Summary of the results comparing the different methods of cystine quantification in the two 
laboratories (Mozley et al). N= 14 patients with cystinuria. N1-4 represents 4 normal patients. S represents 
stock urine. 
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There were no significant differences between the samples measured in our 
laboratory of either the non-alkalinised (P = 0.1976, r2 = 0.7707) or alkalinised 
(P = 0.9309, r2 = 0.6782) samples measured in Southampton and there was good 
correlation between the Biochrom method with the LC-MS method; our 
Biochrom (r2 = 0.8769 and r2 = 0.8750) and Southampton Biochrom (r2 = 0.8728 
and r2 = 0.0789). 
 
When assessing the pre-alkalinised and non-alkalinised samples, there was no 
statistical difference found and the correlation using both instruments was poor 
(LC-MS r2 = 0.6565, Southampton Biochrom r2 = 0.3353). It was observed in the 
two patients (number 12 and 14) with the highest cystine concentrations had a 
higher concentration in the alkalinised samples compared with the non-
alkalinised samples although this was not statistically validated. We hypothesize 
from this that alkalinisation may affect cystine concentration in highly 
concentrated samples although we have not formally tested this. We continue to 
use the Biochrom method for the quantification of urinary cystine in our 
laboratory. 
 
We evaluated the prognostic value of spot urinary measurements of cystine, 
lysine, arginine and ornithine with respect to stone formation in patients with 
cystinuria. We hypothesized that stone episodes would correspond to a peak in 
the levels of urinary dibasic amino acids. 
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3.2 Patients and Methods 
Data was collected between August 2008 to February 2014. A sample of urine 
was collected at each patient visit and sent for measurement of urinary dibasic 
amino acid measured using the Biochrom method (Biochrom 30 Amino Acid 
Analyzer).  Amino acid values were measured as millimoles per mole of 
creatinine (umol/mmol Cr). Follow up ranged from three to twelve monthly. At 
each clinic visit, patients had a renal ultrasound scan for detection of stones. 
Patients with less than one year radiological follow up were excluded.  
 
New stone formation (NSF) was defined as evidence of new stones or an 
increase in size of existing stones seen on imaging as compared with baseline 
imaging. Thus, first clinic visit for each patient with at least six months follow up 
was used. Imaging was analysed for NSF at the time of clinic, three and six 
months prior to clinic, three and six months post clinic.  
 
The levels of the urinary dibasic amino acids were compared between patients 
who had NSF and those with stable disease at each of the time points. The levels 
of the urinary dibasic amino acids were also compared between those with stone 
formation over a year and those without. We used D’Agostino-Pearson test to 
test the normality of our data and Mann U Whitney test was used to compare 
with levels between the two groups. A p value <0.05 was considered significant. 
Analysis was performed using Graph Pad Prism 5.0.  
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3.3 Results 
64 patients were included in the study. 33 additional patients were excluded as 
they had a follow up of less than one year. These were patients who were either 
recently referred with less than one year follow up data or seen as a one-off 
review with routine imaging performed at their local hospital. There were 32 
male and 32 female patients with a median age of 42 years (range 7-73).  13 
patients were taking a thiol at the time of the urine sample (4 taking 
penicillamine, 9 taking tiopronin). 
 
39 patients (61%) had radiological evidence of new stone formation over the 
one-year period.  11 of the 13 patients taking a thiol (85%) had evidence of new 
stone formation during this period. 
 
The levels of each of the urinary dibasic amino acid for patients with new stone 
formation at the time of clinic, within three months and six months inclusive are 
represented below.  
  
 72 
 
 
 
Figure 3.3 The levels of each of the urinary dibasic amino 
acid (cystine, lysine, arginine and ornithine) were 
compared between those new stone formation and those 
with stable disease (Pardy et al 20114).  
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There was no statistically significant relationship between the levels of cystine, 
lysine, arginine and ornithine at each time point. There was a statistically 
significant higher level of ornithine in patients with NSF than in patients with 
stable disease at three and six months prior to stones seen on ultrasound. 
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Figure 3.4 Comparison of levels of urinary dibasic amino acid (cystine, lysine, arginine, 
ornithine) between patients with new stone formation and those with stable disease at time 
of ultrasound imaging time = 0 (adapted from Pardy et al 20114). Patients with evidence of 
new stone formation defined as new stones or stone growth seen on imaging compared with 
baseline had a statistically significant higher level of urinary ornithine (p=0.009). Patients 
with NSF appear to have higher levels of urinary arginine than patients with stable disease, 
but this was not statistically significant. There were no differences in the levels of urinary 
cystine or lysine between NSF and those with stable disease.  
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3.3.1 Subgroup analysis of patients taking thiol medication 
 
A subgroup analysis was performed on patients taking thiol medication. There 
was no association between the levels of cystine, lysine and arginine and new 
stone formation at any time point. The association between urinary ornithine and 
new stone formation at three and six months prior to the urine sample was 
maintained, but no association was shown at 0, 3 and 6 months after the urine 
sample. Only two patients taking thiol medication had no evidence of stone 
formation over a one-year period prohibiting any statistical analysis.  
 
3.4 Discussion 
Cystinuria is a result of the accumulation of urinary cystine. Therefore, it would 
seem reasonable to hypothesize that the higher the levels of urinary cystine, the 
greater the likelihood of stone formation. In this study, we investigated the utility 
of urinary cystine and the other dibasic amino acids as clinical markers for 
predicting stone formation. Investigating the prognostic utility of spot urinary 
cystine and the other non-cystine dibasic amino acids has never previously been 
examined. 
 
Our results do not demonstrate a correlation between urinary cystine levels and 
new stone growth. There are several possible explanations to account for this. 
Firstly, there are previously described limitations in urinary cystine 
measurement; it exists in soluble and insoluble form and only the soluble form is 
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measured, the cystine solubility is affected by factors such as pH and 
temperature, and the majority of cystine assays do not distinguish between free 
urinary cystine and cystine bound to thiol-binding complexes, both of which are 
soluble.  
 
In addition, all cystine quantification methods require the acidification of the 
samples at some stage. In preparation for ion-exchange chromatography, the 
urine is diluted with a loading buffer of pH 2. Carla et al showed in in vitro 
studies that the solubility of cystine demonstrates a U-shaped pattern, that is, at a 
pH of less than 2, the solubility of cystine increases giving rise to the possibility 
that the effects of acidification may be of minimal consequence71. Dolin et al 
have described a method of increasing the solubility of cystine in solution by the 
addition of sodium bicarbonate to a pH of 972. We have not been able to replicate 
this in our laboratory and have found the presence of cystine crystals in urine 
despite the addition of sodium bicarbonate to those samples. 
 
In our prior study, we compared the measurement of urinary cystine using two 
different methods; HPLC and LCMS with alkalinised and non-alkalinised 
samples. The results demonstrate no difference in measurement of urinary 
cystine by the two methods and no difference in alkalinised versus non-
alkalinised samples. Two patients however did demonstrate higher 
concentrations in alkalinised samples and further evaluation of this is needed. 
Although methods of cystine supersaturation have been described in literature as 
having prognostic value, currently, the methods require long sample preparation 
 77 
and dangerous reagents which may not be suitable for routine testing in a 
standard hospital diagnostic laboratory18.  
 
We evaluated the prognostic value of the other urinary dibasic amino acid on 
stone formation. There was no statistically significant difference in levels of 
urinary lysine in patients with NSF compared to those with stable disease. There 
is some evidence to suggest that there may be a separate transport system 
separating lysine from the other dibasic amino acids73-75. There are several 
differences in the handling of urinary cystine and lysine as highlighted in studies 
on rats76. Cystine and lysine share a high-affinity system, however a low-affinity 
system exist which is unshared. In cortical slices, cystine transport is sodium 
dependent whereas lysine is sodium independent. Lysine is transported against a 
concentration gradient whereas cystine is not76.  
 
There was a significant difference between the levels of urinary ornithine in 
patients with evidence of NSF at 3 and 6 months prior to production of urine 
sample (p=0.021 and p=0.04 respectively). There was however no association in 
levels of ornithine at time of urine sample, 3 and 6 months post urine sample. 
This suggests perhaps the measurement of urinary ornithine may reflect a 
propensity for stone formation with a lag period of 3 – 6 months. This is 
potentially useful in predicting which patients are likely to form stones. The use 
is limited however to patients who are on lifestyle modification and dietary 
therapy only, and may not be useful in patients on thiol medication as thiol-
binding medications specifically target urinary cystine and we do not know of 
any effect on urinary ornithine.  
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Our results show that although NSF have higher levels of urinary arginine than 
patients with stable disease, this was not statistically significant (p=0.06). This 
may be limited by a small sample size. We also observed that individual levels of 
urinary dibasic amino acids vary; some patients have proportionally higher levels 
of one urinary dibasic amino acid to another. More research is needed to 
understand the interactions between the individual dibasic amino acids. 
 
Other methods to quantify urinary cystine including colorimetric methods such 
as cyanide-nitroprusside and spectrophotometry, and other forms of HPLC with 
or without derivatisation were not explored in this study. Furthermore, we still 
need a better understanding of what factor facilitate crystal formation and recent 
invitro studies suggest that inosine, vanillylmandelic acid and guanosine may 
have a role77. Understanding how cystine is handled by the kidneys and the 
factors that promote stone formation can offer potential insight into new targets 
for therapy in cystinuria.  
 
3.5 Conclusion  
 
The quantification of spot urinary cystine does not appear to be a useful disease 
marker in the monitoring of disease activity in patients with cystinuria. Urinary 
ornithine and possibly arginine may reflect a propensity to stone formation 
however the use of this is limited to patients on lifestyle and dietary therapy only 
as lifestyle and dietary measures aim to affect cystine levels only. In our 
experiment, we have not been able to successfully replicate the dissolution of 
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cystine crystals by the addition of sodium bicarbonate to the samples as 
described by Dolin et al72. In the next chapter, we explore the utility of 
crystalluria as a clinical marker for disease activity. 
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4 The Diagnostic value of 
Crystalluria 
 81 
 
4.1 Introduction 
 
A predictive clinical marker of stone growth and burden would be particularly 
useful in the long-term management of patients with cystinuria. There are 
currently no guidelines regarding the frequency to which these patients should be 
seen in clinic. An optimal follow-up regimen would be tailored to the disease 
burden of individual patients, ensuring that review is frequent enough not to miss 
significant stone formation, allowing pre-emptive intervention if necessary to 
prevent stone related complications. If a urine sample with crystals can predict 
the presence of stone formation or new stone growth, it may be a useful adjunct 
or even a substitute to frequent imaging and clinic visits which compromise 
patient's lifestyle and increase cost of healthcare services.  
 
The measurement of free urinary cystine alone is not an accurate reflection of 
total urinary cystine as it exists in both soluble and insoluble form and is affected 
by factors such as urine volume and pH18,64,70. Furthermore, current cystine 
assays do not distinguish between free urinary cystine and the cystine bound to 
thiol-drug complexes which are used in the treatment of cystinuria. Hence, no 
correlation has been found between the levels of urinary cystine and stone 
episodes4. Given that urinary crystalluria is a necessary step in stone formation, 
we hypothesized the measurement of urinary crystalluria may be useful clinically 
to predict stone episodes. If the presence of crystalluria can predict stone 
formation, this could be used as a point of care test and replace the need for 
frequent clinic attendance and ultrasound imaging. However, the correlation 
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between urinary crystalluria and presence of stones or new stone growth needs to 
be robust enough not to miss significant stone episodes. Stone formers have 
previously been demonstrated to exhibit a higher cystine crystal volume than 
non-stone formers68, however, the technique described is not readily available in 
standard hospital diagnostic laboratories, and could not readily be adapted as a 
point of care test. This is the first study to investigate whether urinary crystalluria 
can be reliably used as a diagnostic marker for the presence of stone disease and 
new stone growth. 
 
In this study we aim to assess the feasibility of using crystalluria as a clinical 
marker for the presence of stones or new stone growth. However, if crystalluria 
is to be routinely used as a marker for disease activity in cystinuria, then the 
association between urinary crystals and new stone growth needs to be robust. 
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Figure 4.1 Urinary cystine crystals (Courtesy of Cystinuria UK) 
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Urinary crystalluria has been shown to be highly predictive of stone recurrence 
in calcium stone formers67. Daudon et al have shown that the volume of crystals 
(Vcrys; defined as 0.65xNxL2xT where N=number of cystine crystals per mm3, 
L=average length of crystals and T=average thickness of crystals) is significantly 
higher in patients with recurrent stone formation68. This technique, however, is 
time consuming and not readily available in a standard hospital diagnostic 
laboratory. In contrast, the number of urinary crystals can be easily determined. 
However, it is not known whether the number of urinary crystals in cystinuria is 
prognostic with respect to stone formation78. Prior studies on urinary crystalluria 
have used the Malassez counting chamber67,68. We were keen to compare the 
utility of the Malassez counting chamber with cytospin methods which could 
potentially be automated.  Previous studies measuring crystalluria have used 
early morning urine (EMU) samples, as they were considered to represent the 
most saturated sample in a 24-hour period22,24,26,79. We sought to compare the 
predictive value of crystalluria in EMU with a mid-morning Clinic Urine (CU) 
sample, which we feel may be more readily applied in clinical practice. 
 
We investigated the efficacy of crystalluria as a clinical marker for disease 
activity in patients with cystinuria. Specifically, we looked at: 1. The association between the presence of urinary crystals in EMU and CU 
and samples with the presence of stones and new stone growth	
2. The utility of the Malassez counting chamber with cytospin methods for 
measurement of urinary crystalluria 
3. The correlation between the number of urinary crystals and presence of 
stones and new stone growth 
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4.2 Materials and Methods 
 
At each clinic visit, patients were asked to bring an EMU sample and to provide 
a CU sample for measurement of urinary crystals. They all underwent an 
ultrasound scan by our uroradiologist at the same consultation. All patients 
included in the analysis had a least one previous baseline ultrasound for 
comparison. New stone growth (NSF) was defined an increase in stone size or 
new stones reported on ultrasound scan as compared with baseline ultrasound. 
Stable disease include patients who had no stones on their scan or stones that 
were present on their previous ultrasound scan and remain stable in size. To 
avoid patient bias, only the first urine sample for each patient was analysed. 
Samples were excluded if it was the patient’s first visit as no old scan was 
available for comparison, if they had bladder stones or stents in-situ, and where 
the ultrasound scan was inconclusive.  
 
The majority of the urine samples were processed on the same day in the hospital 
diagnostic laboratory. Samples that could not be processed on the same day were 
kept in a fridge at 4 degrees Celsius and processed the next available day. 
Sample preparation and counting methods were performed by Dr Soma Pillay 
(Consultant Cytopathology), Dr Ashish Chandra (Consultant Cytopathologist) 
and their team. The samples were first gently mixed using a rotamixer. Neat 
urine was aspirated into a capillary tube, allowed to diffuse onto the Malassez 
cell counting chamber of 0.2mm depth (CML, Nemours, France), and examined 
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by light microscopy. The number of crystals were counted on the entire chamber 
and the results expressed as number of crystals per mm3.  
 
The number of urinary crystals for each sample was also determined using 
cytospin cytocentrifuge technique. Again, the samples were first gently mixed 
using a rotamix. A standard cytospin protocol was used; 0.25µl of neat urine 
from each sample was spun at 600g for five minutes, then placed on a standard 
microscopy slide and examined using a standard light microscope (Olympus 
BX53).  
 
Where the sample tested had more than 1000 crystals per mm3, the crystals 
formed aggregates and it was impossible to count the crystals individually. It was 
therefore recorded as >1000. For the analysis, the cut-off value was taken to be 
1000. The correlation between the presence of crystals and presence of stones 
seen on ultrasound imaging or new stone growth was compared using the Chi 
square test. ROC analysis was performed to assess the utility of urinary crystals 
as a diagnostic test for the presence of stones and new stone growth. We used 
D’Agostino-Pearson test to test the normality of our data and Mann-U Whitney 
was used to compare the number of crystals between patients with stone(s) or 
new stone growth and those with no stones or stable disease. A p value <0.05 
was considered significant. Statistical analyses were performed using SPSS 
(IBM, Version 22.0) and ROC analyses were performed using MedCalc 
software80 (MedCalc software Version 13.2.2, Belgium).  
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4.3 Results 
 
63 paired patients samples (EMU & CU) were analysed between 1st of Aug 2010 
and 31st of July 2012. To avoid patient sample bias, only the first paired sample 
for all patients was analysed as including all urine samples would bias the 
analysis towards patients who were seen more frequently in clinic and therefore 
provided more urine samples. These are potentially patients with more severe 
disease and more likely to have urinary crystals and stones on ultrasound. 
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Patient Cohort Frequency 
  
No of patients 63 
Age at Presentation 23 
Age Range 9 mths to 61 yrs 
M:F ratio 1.25:1 
No of patients with stones seen on US 31 
No of patients with new stone growth 27 
  
Total number of samples 126 
No of samples with crystals present 56 
Stones vs no stones on US 35(63%) vs 21(37%) 
New stone growth vs stable disease on US 27(48%) vs 29(52%) 
No of samples without crystals 70 
Stones vs no stones on US  26(37%) vs 44(63%) 
New stone growth vs stable disease on US 17(24%) vs 54(77%) 
No of samples with >1000 crystals 14 
Stones vs no stones on US  11(79%) vs 3(21%) 
New stone growth vs stable disease on US 7(50%) vs 7(50%) 
Table 4.1 Patient demographics and sample analysis. Subgroup analysis of samples with 
crystals present, samples without crystals and samples with more than 1000 crystals.  
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Figure 4.2 The number of crystals associated with EMU and CU samples.  
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4.3.1 Pilot study comparing the Malassez counting chamber and cytospin 
methods 
 
To investigate the optimum method of quantifying crystalluria, all samples were 
initially analysed using both the Malassez counting chamber method and the 
cytospin method. Data was obtained from 40 patients. There was no statistically 
significant difference between the presence of urinary crystals and presence or 
absence of stones on ultrasound nor for new stone growth (NSG) versus stable 
disease for EMU using both methods using the chi-square test (stones, Malassez 
chi-square test =2.71, d.f.=1, p=0.10, Cytospin chi-square test=1.52, d.f.=1, 
p=0.22; NSG, Malassez Chi-square test=0.89, d.f.=1, p=0.35, Cytospin chi-
square test =1.15, d.f.=1, p=0.28). When comparing the CU samples however, 
there was a statistically significant difference between the presence of crystals in 
patients with stones detected on ultrasound compared to patients with no stones 
using both methods (Malassez chi-square test=5.65, d.f.=1, p=0.02, Cytospin chi-
square test=6.42, d.f.=1, p=0.01). There was also a significant difference when 
comparing the presence of crystals between patients with NSG on ultrasound 
compared with patients with stable disease using cytospin but not the Malassez 
counting chamber (NSG Malassez chi-square test=2.88, d.f.=1, p=0.09, Cytospin 
chi-square test=5.18, d.f.=1, p=0.02). The area under the ROC was highest for 
clinic urine samples analysed by the cytospin method (AUC 0.70; 95% CI 0.53 
to 0.84)81. 
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  AUC SE  95% CI   
EMU Malassez 0.61 0.07 0.45 to 0.77 
EMU Cytospin 0.66 0.08 0.49 to 0.80 
CU Malassez 0.66 0.07 0.49 to 0.80 
CU Cytospin 0.70 0.07 0.54 to 0.84 
Figure 4.3 ROC curve of number of crystals in determining presence of stone(s) using both 
cytospin and Malassez counting chamber methods 
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  AUC SE  95% CI   
EMU Malassez 0.57 0.077 0.41 to 0.73 
EMU Cytospin 0.62 0.089 0.46 to 0.77 
CU Malassez 0.60 0.076 0.43 to 0.75 
CU Cytospin 0.664 0.082 0.50 to 0.81 
Figure 4.4 ROC curve of number of crystals in determining new stone growth using both 
cytospin and Malassez counting chamber methods 
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4.3.2 Comparison of EMU with CU samples 
 
The use of the Malassez counting chamber was abandoned after our pilot data 
suggested that it was less effective than cytospin (see previous section). When 
comparing EMU samples, there was no association between the presence of 
crystalluria in patients with stones seen on ultrasound imaging and those without 
(chi-square test=1.92 d.f.1 p=0.17). There was also no association between the 
presence of urinary crystals with new stone growth (chi-square test=1.32, d.f.=1 
p=0.25). When comparing the CU samples however, there was a statistically 
significant difference between the presence of crystals seen in patients with 
stones seen on ultrasound imaging and those without (chi-square test=5.86 d.f.=1 
p=0.02). The likelihood ratio was 5.96, d.f.=1 (p=0.02). There was a statistically 
significant difference between the presence of crystals seen in patients with NSG 
compared to those without (chi-square test=8.10 d.f.=1 p=0.004). The likelihood 
ratio was 8.11 d.f.=1 (p=0.004). 
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  AUC SE  95% CI   
Clinic Urine 0.66 0.06 0.53 to 0.78 
Early Morning Urine 0.62 0.07 0.49 to 0.74 
Figure 4.5 ROC curve comparing EMU and CU in determining the presence of stone(s)  
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  AUC SE  95% CI  
Clinic Urine 0.67 0.07 0.54 to 0.79 
Early Morning urine 0.60 0.07 0.47 to 0.72 
Figure 4.6 ROC curve comparing EMU and CU in determining new stone growth 
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Receiver operator curves for EMU and CU for all 63 patients are seen above. 
The area under the curve for crystals and presence of stones for CU samples was 
0.661 (95%CI 0.53 to 0.78). The sensitivity and specificity was 56.7% (95% CI 
37.4-74.5%) and 75.8% (95% CI 57.7-88.9%) respectively. The positive 
predictive value (PPV) was 68% (95%CI 46.5-85.1%) and negative predictive 
value (NPV) was 65.8% (95%CI 48.7 – 80.4%). The AUC for crystals and new 
stone growth for CU samples was 0.67 95%CI 0.54 to 0.79. The sensitivity and 
specificity of the presence of crystals in CU samples to predict new stone growth 
were 56% (95%CI 34.9 to 75.6%) and 80.5% (95%CI 65.1 to 91.2%) The PPV 
and NPV were 63.6% (95%CI 40.7 to 82.8%) and 75% (95%CI 57.7 to 86.8%). 
The sensitivity and specificity of the presence of crystals in CU samples to 
predict new stone growth was 59.09% (95%CI 36.4 to 79.3) and 75.61% (95%CI 
59.7 to 87.6%) respectively at a level of >28 crystals as calculated by the optimal 
criterion.  
 
There was a statistically significant difference in the number of urinary crystals 
in patients with stones compared with those without for CU samples (Mann-U 
Whitney; median=41, IQR=600 vs median=0, IQR 21, p=0.01). There was a 
statistical difference between the number of crystals (49, IQR 525 vs 0, IQR 40, 
p=0.01) between patients with new stone growth and patients with stable disease 
for CU samples. There was no difference between the number of crystals 
between patients with stones and those without for EMU samples (median=12 
IQR=400 vs median=0, IQR=60, p=0.08). Likewise, there was no difference 
between patients with new stone growth and stable disease for EMU samples 
(median=24, IQR=450 vs median=0, IQR=88, p = 0.15). 
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4.4 Discussion 
 
There is no reliable marker of disease activity currently available to clinicians 
managing patients with cystinuria37. Our results show an association between the 
presence of crystalluria and presence of stones for CU samples but the 
correlation is not robust enough for the use of crystals as a single diagnostic test.  
 
Previous studies have used the Malassez counting chamber for the measurement 
of urinary crystals in other types of stone disease and also in the measurement of 
cystine crystals volume67,68. We compared the Malassez counting chamber with 
cytospin and found that cytospin yielded a higher area under the curve over the 
Malassez counting chamber, particularly for CU samples. We postulate that this 
was because the Malassez counting chamber does not allow large aggregates of 
crystals to fit into the chamber and were discounted from sampling potentially 
leading to an underestimation of the number of crystals, particularly in heavily 
saturated samples. The use of the Malassez counting chamber was subsequently 
abandoned in favour of the cytospin method.   
 
Previously, the EMU was presumed to be the most reliable sample for 
measurement of crystalluria as it represents the most saturated sample during a 
24-hour period due to overnight accumulation of urinary sediment. EMU 
samples have been used in studies of crystalluria for other types of stone disease 
such as calcium composite stones. Our results show that there was a higher 
correlation between the presence of urinary crystals and presence of stones in CU 
compared with EMU samples. We speculate that due to the high concentrations 
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of crystals expected in all cystinuria patients, the concentrated EMU may be an 
oversaturated sample that does not accurately differentiate between patients with 
high and low disease activity.  
 
A patient with CU crystals is four times more likely than a patient without 
crystals to have stones on ultrasound imaging (OR 4.087 95%CI 1.395 to 11.97) 
and five times more likely to have new stone growth (OR 5.250 95%CI 1.739 to 
15.85). 37% (26/70) of samples with no crystals had stones on ultrasound 
imaging. One possible explanation is that the fraction of urine analysed may not 
have adequately sampled crystals that may be present. However, this 
demonstrates that although there was a strong association between the presence 
of crystals and stones, the absence of crystals does not necessarily exclude the 
presence of stones. The overall NPV is 65.8% (95%CI 48.7 to 80.4%).  
 
Furthermore, 11% (14/126) samples had over 1000 crystals per mm3. Where the 
sample tested had more than 1000 crystals per mm3, the crystals formed 
aggregates and it was impossible to count the crystals individually. It was 
therefore recorded as >1000. For the analysis, the value was taken to be 1000. 
This may decrease the sensitivity of the results and may partially account for the 
lack of statistical significance in the EMU analyses. The NPV of more samples 
with more than 1000 per mm3 is 56.4% (95%CI 42.3 to 69.7%).  
 
All our patients undergo ultrasound scanning of their kidneys by a uroradiologist 
at each clinic visit to detect stones. Cystine stones are poorly radio-opaque and 
therefore X-ray is not performed routinely. Arguably, ultrasound may 
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underestimate the stone burden and CT would be the gold standard19. Repeated 
CT imaging however, would expose patients to excessive radiation and therefore 
not an appropriate tool for follow-up given the frequency to which many of these 
patients are seen in clinic (3 monthly to annually). Factors that may affect the 
diagnosis and interpretation of stones on ultrasound imaging include the presence 
of hydronephrosis, stone abutting renal sinus fat, the presence of bowel gas and 
body habitus19. The overall sensitivity and specificity of ultrasound for renal 
stones in the literature is 45% and 88% respectively82.  From our clinical 
experience, we believe the sensitivity and specificity of the ultrasound performed 
by our specialist uroradiologist is likely to be higher than that reported in 
literature. In our study, we have used our ultrasound findings as the gold standard 
comparison. Our results suggest that the use of urinary crystals may have 
comparable sensitivity and specificity to ultrasound imaging as reported in the 
literature. It would be interesting to compare the effectiveness of crystalluria 
measurement with cross-sectional imaging techniques, however, the numbers are 
likely to be small because of the avoidance of CT in this patient group. 
 
Where possible, the urine samples were processed on the same day as the urinary 
pH of a sample may decrease the longer the sample is left out unprocessed, 
affecting the amount of crystals that precipitate83,, This may have practical 
implications if crystalluria is to become a point of care test for patients.  Another 
study limitation is the small sample size, although this represents a relatively 
large cohort in a single institution for such a rare disease. Larger patient numbers 
can be obtained by collaboration with national and international groups such as 
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the UK Rare Renal Disease cystinuria Group,  and the USA Rare Kidney Disease 
Consortium84,85.  
 
4.5 Conclusion 
Our study suggests that EMU in cystinuria patients may be an oversaturated 
sample and may not accurately differentiated between patients with high and low 
disease activity. There is a higher correlation between presence of urinary 
crystals and presence of stones in CU samples. Furthermore, we found that the 
presence of urinary crystals in patients with cystinuria is associated with 
presence of stone formation and new stone growth when using the cytospin 
method and clinic urine samples. The sensitivity and specificity of using 
crystalluria to determine the presence of stones or new stone growth is 
comparable to that of ultrasound. However more studies are required to fully 
characterize the use of crystalluria as a marker for disease activity, in particular 
comparing crystalluria to more sensitive cross sectional imaging. Whilst, we 
cannot currently recommend the use of crystalluria as a single diagnostic tool for 
identifying stone episodes, it may be a useful adjunct and requires further 
investigation. 
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5 The Genetic Diversity of 
Cystinuria in a UK Population 
 102 
 
5.1 Introduction 
 
Over 200 mutations have been described in Cystinuria but none have been 
reported in a UK population29,86-91. We have over 80 patients coming through our 
clinic from all over the UK which allows us the unique opportunity to study one 
of the largest group of cystinuria patients. There have been few studies 
examining the genotype-phenotype correlation in cystinuria. In one study, 50% 
of patients with type A cystinuria present with stone disease in their first decade 
of life and another 25% in their teenage years 34. Another study comparing type 
A and B patients showed no difference in clinical or biochemical presentation 
between the two types of cystinuria10.  
 
Given the number of different mutations described in Cystinuria, we devised a 
method of classification of patients with type A cystinuria into two groups for 
comparison. Group M included all patients with at least one missense mutation 
and Group N included all patients with a combination of all other types of 
mutations. We hypothesize that patients with missense mutations have less 
severe disease as missense mutations result in a change to a single amino acid 
within the protein compared with all other types of mutations (nonsense, 
frameshift, splice site, deletions and duplications) which cause larger genomic 
alterations. The levels of urinary dibasic amino acids and clinical parameters 
including age at presentation, number of stone episodes and number of 
interventions were compared between patients in groups M and N. We were 
unable to use this classification when looking at SLC7A9 mutations as all except 
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one patient had at least one missense mutation therefore precluding statistical 
analysis. 
 
The aim of this study was threefold;  
1. To identify the genetic mutations in a UK cohort of patients with 
cystinuria 
2. To compare the urinary phenotype of type A patients with at least one 
missense mutation and type A patients with all other types of mutations.  
3. To compare clinical phenotype (age of disease presentation, number of 
stone episodes and interventions) of type A patients with at least one 
missense mutation and type A patients with all other types of mutations.  
 
5.2 Patients and Methods 
 
All patients who attended the clinic between 1st August 2008 and 31st August 
2012 were invited to participate in our genetic study. A single peripheral blood 
sample was taken for DNA sequencing and Multiplex Ligation-dependent Probe 
Amplification (MLPA). In addition, urine samples were taken at each clinic visit 
for measurement of spot urinary dibasic amino acids namely cystine, lysine, 
arginine and ornithine.  
Ethical approval and adherence to best practice was obtained according to 
institutional guidelines. 
5.2.1 DNA sequencing  
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DNA sequencing was performed using standard Sanger sequencing technique by 
RM92. Genomic DNA, extracted from the peripheral lymphocytes, was amplified 
by polymerase chain reaction (PCR) into 24 amplicons covering the whole exon 
and exon/intron boundaries of all coding exons of SLC3A1 and SLC7A9. A tag 
sequence was incorporated into the ends of each amplicon to facilitate the use of 
a universal primer in the sequence reaction of all amplicons. Products were 
detected on an ABI3730 DNA Analyser (Applied Biosystems) and analysed 
using Mutation Surveyor software (SoftGenetics). The clinical effect of each 
mutation detected was predicted using Alamut software (Interactive 
Biosoftware).  
 
5.2.2 Multi-ligand Probe Amplification 
 
MLPA was also performed to detect large deletions and duplications, that span 
one or more exon, which cannot be detected by DNA sequencing. However, the 
disadvantage is that point mutations can give false results and may look like a 
deletion as the probe doesn’t bind. Two MLPA kits were used, one with all 
exons of the SLC3A1 as well as exon 13 of SLC7A9, and one kit with all coding 
exons of SLC7A9.  Synthetic probes previously described93 were used with 
control probes (on patients with known disease) from the P200 kits supplied by 
MRCHolland.  250ng of Genomic DNA and 50pM of each synthetic probe were 
used in the standard MLPA protocol, as described by MRC Holland for custom 
made MLPA assays using P200 control probes.  Products were detected on an 
ABI3730 (Applied Biosystems) and analysed using GeneMarker software 
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(SoftGenetics). Samples were run with patients without cystinuria as well as 
samples without DNA.  The analysis was also rerun for validity.  
   
5.2.3 Genotype-phenotype Analysis 
 
Data on patient demographics, ethnicity and age at first stone presentation and 
levels of urinary dibasic amino acids were recorded over the four-year period. In 
addition, data on the number of stone episodes and interventions including 
Extracorporeal Shockwave Lithotripsy (ESWL), Ureteroscopy (URS), 
Percutaneous Nephrolithotomy (PCNL) or open surgery where available was 
recorded for the four-year period. 
 
Statistical analysis was performed using Graphpad software. The levels of 
urinary dibasic amino acids, age of disease presentation, number of stone 
episodes and interventions were compared between type A and B patients using 
Mann-Whitney U test. Results were reported as median and interquartile range. 
A p value of <0.05 was deemed as statistically significant.  
 
In order to examine whether or not there was any correlation between a patient’s 
genotype and clinical phenotype, we divided patients with SLC3A1 mutations 
into two groups. Group M included all patients with at least one missense 
mutation and Group N included all patients with a combination of all other types 
of mutations. Missense mutations result in a change to a single amino acid within 
the protein. All other mutations include nonsense, frameshift and splice site, and 
whole exon deletions and duplications. The levels of urinary dibasic amino acids 
 106 
and clinical parameters including age at presentation, number of stone episodes 
and number of interventions were then compared between patients in group M 
and N using Mann-Whitney U test. Again, the results were reported as median 
and interquartile range. A p value of <0.05 was deemed as statistically 
significant. 
 
5.3 Results 
 
In total, 74 patients underwent genetic testing, 33 female 41 male. 85% (63/74) 
patients were white-British. Mean age at presentation to the clinic was 39.5 years 
(14-73). Mean age of presentation of disease was 23.9 years (0 – 61). The mean 
number of stone episodes per patient per year was 0.52 (range 0-3.75). The mean 
number of interventions per patient per year was 0.59 (range 0-2.75). There were 
five pair siblings94. 
 
41 patients had homozygous or compound heterozygous sequence variants in 
SLC3A1 including one where one of the sequence change was a variant of 
unknown clinical significance. 23 patients had homozygous or compound 
heterozygous sequence variants in SLC7A9 including 6 patients who had a 
variant of unknown significance. One patient had three sequence variants in 
SLC7A9 however two of which were of unknown significance. Three patients 
had a single heterozygous mutation in SLC7A9. Three patients had sequence 
variants in both genes (Type AAB), however the SLC7A9 variant was of 
unknown significance. No mutations were found in three patients.  
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There were 56 different pathogenic mutations identified. The commonest 
mutation in SLC3A1 was Ex5_9Dup 27% (24/88). The commonest mutation in 
SLC7A9 was c.614dupA (p.Asn206fs) 20% (11/55). p.Pro482Leu which affects 
more than 84% of the identified SLC7A9 alleles in the Japanese population is 
present in one patient who is half Japanese90. 
 
 
Figure 5.1 The different pathogenic mutations in SLC3A1 including 20 missense, 1 spice 
site, 5 frameshift, 1 nonsense and 4 deletions and duplications (31 in total including 9 new 
mutations).  
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Figure 5.2 The different pathogenic mutations in SLC7A9 including 15 missense, 4 spice 
site, 4 frameshift and 2 deletions (25 in total including 14 new mutations). 
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23 previously unreported sequence variants were identified in our population of 
patients, three of these were of unknown clinical significance. There were three 
further variants of unknown significance which have been previously reported in 
literature. 
 
There was no statistical difference in the levels of urinary dibasic amino acids 
between type A and B patients; cystine (177.7umol/mmol Cr IQR 139.3 to 221.8 
vs 182.0umol/mmol Cr IQR 150.5 to 231.0 p=0.8327), lysine (613.0umol/mmol 
Cr IQR 549.0 to 729.6 vs 643.3umol/mmol Cr IQR 560.6 to 837.7 p=0.5307) 
arginine (226.9umol/mmol Cr 130.9 to 345.0 vs 294.3umol/mmol Cr IQR 76.19 
to 391.2 p=0.4083) and ornithine (108.7umol/mmol Cr IQR 80.04 to 144.0 vs 
111.0umol/mmol Cr IQR 79.19 to 159.6 p=0.8080). There was also no difference 
in age of presentation of disease (19.00 IQR 12.00 to 28.00 vs 16.00 IQR 14.00 
to 35.00 p=0.7661), number of stone episodes per year (0.2500 IQR 0.0 to 
0.5000 vs 0.2500 IQR 0.00 to 0.5000 p=0.7915) or number of interventions per 
year (0.5000 IQR 0.0 to 1.000. vs 0.2500 IQR 0.0 to 1.000 p=0.5569) between 
Type A and Type B patients with cystinuria. There were two SLC7A9 
heterozygotes with a late onset of presentation of disease and low levels of 
dibasic amino acids. Type AB patients appeared to present with a later onset of 
disease (median 40) compared with Type A (median 19) and B patients (median 
16) although this is based on three AB patients only.  
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Figure 5.3 Comparison of age at presentation of disease between Type A, B and AB 
patients. There were only 3 type AB patients therefore it was not possible to perform 
statistical analysis on this group. 
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Patients with mutations in SLC3A1 were divided into group M and group N for 
comparison. There was no statistical difference between the levels of urinary 
cystine (169.8umol/mmol Cr IQR 138.8 to 214.7 vs 218.7umol/mmol Cr IQR 
168.3 to 255.0 p=0.2343) in the two groups. There was however a statistical 
difference between the levels of urinary lysine (607.5umol/mmol Cr IQR 505.3 
to 663.2 vs 735.1umol/mmol Cr IQR 676.1 to 857.0 p=0.0171), arginine 
(178.8umol/mmol Cr IQR 81.26 to 293.1 vs 386.1umol/mmol Cr 365.5 to 413.7 
p=0.0008) and ornithine (98.76umol/mmol Cr IQR 79.24 to 135.9 vs 
162.5umol/mmol Cr IQR 130.8 to 168.4 p=0.0211). This did not translate to a 
significant difference in age of presentation of disease (21 IQR 12.00 to 34.00 vs 
16.00 IQR 14.50 to 19.50 p=0.1236), number of stone episodes per year (0.2500 
IQR 0.0625 to 0.5000 vs 0.2500 IQR 0.0 to 1.000 p=1.000) or number of 
interventions per year (0.3750 IQR 0.0 to 1.000 vs 1.000 IQR 0.0 to 1.250 
p=0.386).  
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Figure 5.4 Comparison of levels of urinary dibasic amino acids between Group M and N.  
 
Figure 5.5 Comparison of stone episodes and interventions between Group M and N 
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5.4 Discussion  
 
This is the largest single population study on genetic mutations in cystinuria in 
literature and the first in the UK. Figure 5.1 shows all the mutations found in 
both genes. Interestingly, we found 23 novel mutations not previously described 
in literature in our population. There were six variants of unknown clinical 
significance, three of which have not been previously reported. Variants were 
classified as being of unknown significance based on in silico predictions, 
frequency of the variant in studies reported in The Single Nucleotide 
Polymorphism Database (dbSNP), and presence or absence of other cystinuria 
variants detected. For example, one variant was found in a patient who had a 
well-described SLC3A1 mutation in the other allele. We believe the variant is 
likely to be pathogenic as no other mutation was found in this patient.  
 
The majority of patients in this cohort were Caucasian (85%). The mutational 
diversity in our population is similar to pattern described by other European 
groups 86,88,93,95-97. Ex 5_9Dup was the commonest mutation in SLC3A1 in our 
population with a frequency of 27% (24/88) which has a worldwide frequency of 
4.7%, 28.3% in Germany 29,98. Our commonest mutation in SLC7A9 was 
c.614dupA (20%), which has a worldwide frequency of 7% and 29% in Spain 
29,86,87,89. The new mutations were found in both Caucasians and other ethnic 
groups. 
 
Three patients had a single mutation in SLC7A9. These patients had slightly 
higher levels of all four urinary dibasic amino acids cystine (mean 
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92.65umol/mmol Cr), lysine (mean=306.13umol/mmol Cr), arginine (mean = 
7.25umol/mmol Cr) and ornithine (mean=30.87umol/mmol Cr) than a normal 
population although in the lower range compared with other cystinuria patients. 
This is consistent with the clinical phenotype of obligate heterozygotes. There 
were six further patients who had a pathogenic mutation in SLC7A9 together 
with a variant of unknown significance. One patient had three sequence variants 
in SLC7A9 although two were of unknown significance. Both the variants of 
unknown significance have been seen in other patients with SLC7A9 pathogenic 
mutations. 
 
Interestingly, there were three patients where no mutations were found in either 
genes. One patient had prior stone analysis confirming cystine stone formation. 
This patient had only marginally increased levels of all four urinary dibasic 
amino acids and relatively higher levels of arginine compared with the other 
three dibasic amino acids. A second stone sample sent for analysis showed 
calcium phosphate stone formation whilst on potassium citrate therapy.  
 
The second patient where no mutations have been found with DNA sequencing 
and MLPA had pathologically high levels of all four urinary dibasic amino acids. 
Clinically, he has frequent stone episodes in keeping with a diagnosis of 
cystinuria. There are other such cases reported in literature. It is possible that 
DNA sequencing of exons may in fact potentially miss splice site mutations that 
are embedded in the introns. Mutations in genes not yet discovered may account 
for a handful of such cases 29,99. More recently, Nagamori et al describes from 
studies done with co-immunoprecipitation and mass spectrometry a potential 
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second transporter protein AGT1 found on SLC7A13 which is involved in 
cystine transport and mutations of this gene may lead to disease100.  
 
The third patient underwent a ureteroscopy and laser fragmentation of a stone. 
During follow-up, he was found they had mildly elevated dibasic amino acids to 
normal range. Subsequent stone analysis revealed a calcium oxalate stone.  
 
There were five pairs of siblings. Each pair shared the same mutations as 
anticipated. Despite having the same mutations, the clinical presentation in 
paired siblings was varied. This suggests that other epigenetic and environmental 
factors may play a role in the presentation of the disease.  
 
There was no difference in the clinical presentation of patients between Type A 
and Type B cystinuria which is consistent with the other study in literature 10. We 
had three Type AB patients with cystinuria who all had two SLC3A1 mutations 
and one SLC7A9 variant of unknown significance. All three patients presented 
with a later onset of disease which is again consistent with reports of other Type 
AB patients in published literature 10.  
 
Our prior studies demonstrate that urinary cystine is a poor marker of disease 
activity4. This is in part due to the supersaturation of cystine in the urine which 
precipitates into crystals. Cystine therefore exists in both soluble and insoluble 
form in urine and measurement of free urinary cystine only is not reflective of 
total levels. There are also limitations to current cystine assays as they do not 
distinguish between free cystine and cystine bound to thiol-binding drugs. This 
 116 
may explain why, when comparing patients in group M versus patients in group 
N of the SLC3A1 gene, we found no statistical difference between the mean 
levels of cystine. 
 
When looking at the other more soluble dibasic amino acids, there was a lower 
level of urinary lysine, arginine and ornithine in group M patients compared with 
group N patients. This difference was statistically significant for all three urinary 
dibasic amino acids. One possible explanation for this difference is that the 
presence of a missense mutation leads to a less deleterious effect on protein 
function. A missense mutation causes a change in a single amino acid whereas 
all other mutations (nonsense, frameshift, deletions, duplications and splice site) 
cause larger genomic shifts and are therefore assumed to have a greater effect on 
the protein. This explanation however, does not take into account the individual 
differences between all the different missense mutations. Some missense 
mutations will clearly have a greater effect on protein function than others. For 
example p.Gly105Arg is known to destroy the transporter activity and 
individuals with this mutation are likely to have severe disease101. By grouping 
all patients with missense mutations into one group, the individual differences 
between the different missense mutations are lost. This may in part account for 
the lack of clinical difference in stone episodes and number of interventions 
between patients.  
 
Nevertheless, the results suggest for patients with SLC3A1 mutations, the 
presence of a missense mutation results in lower levels of urinary lysine, arginine 
and ornithine, potentially because the transporter protein is less severely affected 
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potentially due to compensatory effects of another transporter. Patients in group 
M also have lower levels of cystine than patients in group N, however, the lack 
of statistical significance may reflect the limitations of cystine measurement 
rather than a true lack of correlation. This is the first time such a genotype-
phenotype correlation has been demonstrated in cystinuria. It was not possible to 
classify patients with SLC7A9 mutations in the same way because all these 
patients with the exception of one patient had at least one missense mutation. 
Furthermore, the inheritance pattern of SLC7A9 mutations is more complex than 
SLC3A1; whereas SLC3A1 is inherited in an autosomal recessive fashion and 
the less severely mutated allele is assumed to be expressed, SLC7A9 is 
autosomal dominant with incomplete penetrance. It is not possible to quantify the 
contribution of each mutated allele to the overall phenotype. 
 
There was no difference in the age of presentation, number of stone episodes or 
interventions between group M and N patients. In addition to the limitations of 
our classification, there are several other explanations for the lack of clinical 
correlation. Firstly, we chose a four-year period over which we recorded stone 
episodes and interventions. This was because the start of this period represents 
the start of the clinic and data was collected prospectively. The medical records 
prior to this collected time period were often not available to us particularly 
when the patient was referred from other units. We found that patient’s memories 
of stone episodes and interventions that occurred more than four years ago was 
unreliable particularly if they have had a number of procedures and if multiple 
procedures were for treatment of the same stone.  
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The number of interventions was also influenced by the frequency of clinic 
attendance. The more frequently we followed up patients, the more likely stones 
were detected and potentially more likely to intervene earlier than would 
otherwise have occurred if we had waited for patients to present with symptoms. 
Furthermore, all patients who attend our clinic undergo dietary intervention and 
some are on medical therapy to prevent further stone events. All these measures 
interfere with the natural progression of the disease.  
 
In addition to understanding the genetic mutations in a UK population allowing 
for greater insight into the disease, our analysis suggests that for the first time, 
we can correlate a patient’s genotype with biochemical phenotype; patients with 
missense mutations have lower levels of urinary lysine, arginine and ornithine. 
The correlation with cystine remains unclear and further improvements in cystine 
measurement are required to clarify this. This is the first step to a personalised 
approach to the management of patients with cystinuria. Finally, more research is 
still needed to understand what triggers the presentation of stone disease in these 
patients. 
 
In this study, we did not examine the genotype or phenotype of family members. 
By doing so and adding our patients to the International Cystinuria Registry will 
facilitate further larger scale studies in collaboration with national and 
international groups such as the Rare Kidney Stones Consortium and the UK 
Rare Renal Disease cystinuria group (RaDaR) 84,85. Further genetic studies are 
needed to elucidate how single mutations in the SLC7A9 gene can cause disease. 
With the recent discovery of SLC7A13 encoding for a second cystine 
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transporter, investigating mutations in this gene in patients where no mutations 
have been found might further explain these patients’ phenotypes. Furthermore, 
the clinical value of the non-cystine dibasic amino acids is still unclear. In some 
patients we found that they had relatively higher levels of one dibasic amino acid 
over another.  
 
5.5 Conclusion  
 
The UK population of patients with cystinuria are mutationally diverse. We 
found 23 mutations not previously reported in literature. Patients with at least 
one missense mutation in SLC3A1 have lower levels of lysine, arginine and 
ornithine than those patients with all other types of mutations. Further research is 
required at a national and international level in collaboration with groups such as 
the Rare Kidney Stones Consortium and RaDaR. 
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6 The Role of Protein Modelling 
in predicting disease activity  
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6.1 Introduction 
As previously described, patients with cystinuria are clinically and genetically 
diverse. We have found 57 different mutations in our UK cohort of which 23 
have not previously been described94. Frame shift, deletion, duplication, splice 
site and nonsense mutations typically result in large effects on the encoded 
protein and therefore its protein structure or function. Most mutations described 
in Cystinuria however, are missense mutations. A missense mutation is a single 
point mutation, which results in a change to a single amino acid in a protein. 
Some missense mutations can render a protein non-functional whilst others may 
not lead to any appreciable protein change. For many of the missense mutation in 
SLC3A1 or SLC7A9, it is not clear what effect they have on protein function and 
how they lead to disease presentation.  
 
The aim of this study was to use protein modelling to model the rBAT and 
b(0+)AT subunits and identify how the missense mutations identified in our 
cohort may affect protein function. Similar protein modelling approaches applied 
to other conditions such as chronic kidney disease have been successfully used to 
identify candidate genetic variants identified in genome wide association 
studies102,103. Understanding how individual genetic mutations can cause protein 
dysfunction could lead us to a greater insight to the range of clinical phenotypes 
of cystinuria and potentially allow us to predict a patient’s clinical severity based 
on their genotype. This is the first step towards a personalised tailored approach 
to management of patients with cystinuria. 
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6.1.1 The rBAT and b(0+)AT protein unit 
 
SLC3A1 encodes for the neutral and basic amino acid transport protein (rBAT) 
and SLC7A9 encodes for the light chain b amino acid transporter b(0+)AT 13,14. 
The proteins form a dimer linked by a disulphide bridge 15. b(0+)AT consists of 
487 amino acids (53481 Da) with 12 transmembrane helices that form the 
channel through which dibasic amino acids (cystine, lysine, arginine and 
ornithine) are transported into the cell with the exchange of neutral amino acids. 
rBAT is the larger of the two subunits consisting of 685 amino acids (78852 Da), 
with a single transmembrane helix and a large extracellular domain. 
Experimental studies suggest that rBAT may function as a mediator of b(0+)AT 
14,16. Mutations in either of these two genes can result in defective transport of 
dibasic amino acids across the renal tubular membrane and intestine 104,105.  
 
 
6.2 Patients and Methods 
I was responsible for designing this study, collecting the clinical data, and 
performing the data analysis. Dr Mark Wass performed the protein modelling 
and scoring of the mutations. Dr Mark Wass and I contributed equally to the final 
paper. 
6.2.1 Protein Modelling 
 
The protein structures of rBAT and b(0+)AT were modelled using the Phyre2 
web server106 (Figure 2). The rate4site algorithm from ConSurf107 was used to 
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calculate evolutionary conservation of the residues in both genes. Functional 
sites of the protein were modelled using multiple methods. The ligand binding 
sites including the amino acid, sugar and calcium binding sites were modelled 
using 3DLigandSite108,109 and Firestar 110. Pfam was used for predicting the 
active site residues inSLC3A1111. The VarMod webserver was also used to 
investigate the likely functional effects of the mutations 112  
 
The b(0+)AT protein transports dibasic amino acids into the cell in exchange for 
neutral amino acids. There are therefore two sites for amino acid binding, one on 
each side of the transporter. The luminal facing binding site was modelled using 
3DLigandSite and Firestar using the Arginine bound to another related APC 
transport (AdiC, pdb code: 3OBM) 113. To model the intracellular facing 
conformation, the putative binding site identified for ApcT (another member of 
the APC transporter family) was mapped onto our model 114. 
 
Prior studies have proposed that Lys158 in ApcT has a role equivalent to sodium 
in sodium dependent transporters 114. This lysine is conserved in b(0+)AT (Lys 
184) and 3 of the 4 residues coordinating with it are also conserved (G41, I44, 
S312). The residues from the three different sites in b(0+)AT were used as 
indicators of functionally important regions where mutations are likely to affect 
the function of the transporter. 
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6.2.2 Mutation Analysis  
 
A number of mutations have been previously described. Where prior 
experimental studies were available, this was used to predict the effect of the 
mutation in our protein model. For mutations where no prior experimental data 
was available, we used our model to predict how each individual mutation can 
lead to a change in protein conformation.  
 
6.2.3 Genotype-phenotype analysis 
 
The mutations in SLC7A9 were then scored by a non-clinical investigator (MW) 
blind to the clinical data into those predicted to cause a low/low-medium 
effect=1 or high/high-medium effect=2 on protein function. Each patient with 
homozygous/compound heterozygous mutations in SLC7A9 has two mutations 
and therefore were assigned an overall severity score based on the sum of the 
score of each individual mutation. The levels of urinary dibasic amino acids, 
clinical parameters i.e. age of presentation of disease, stone episodes and 
interventions as recorded over a four-year period were then compared between 
patients with a high and low score using the Mann-U Whitney test.  Patients who 
had mutations that were not modelled were excluded from the analysis. 
 
6.3 Results 
A total of 74 patients were genotyped for mutations. There were 41 patients with 
mutations in SLC3A1 including one patient with a variant of unknown 
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significance. There were 23 patients with compound heterozygous mutations in 
SLC7A9 including 6 patients with variants of unknown significance. Three 
heterozygous patients had a mutation in only one allele in SLC7A9. One patient 
had three SLC7A9 mutations although two were unknown variants. Three 
patients had mutations in both genes. We have not found mutations in either 
genes in three patients.  
 
There were 55 different pathogenic mutations in total. There were 20 different 
missense mutations in SLC3A1 and 15 different missense mutations in SLC7A9.  
 
6.3.1  The rBAT protein (SLC3A1 mutations)  
 
The residues predicted to have a potential functional role in the alpha amylase 
domain for sugar binding are: D172, Y175, H215, V258, Y259, F278, M279, 
Q282, S312, D314, A315, F318, E384, D449. Additionally D133, N135, D137, 
N139, D141 are predicted to bind calcium.  
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Figure 6.1 Model of rBAT. The modelled sugar binding site residues are blue and the 
calcium binding is light blue 
 
  
 127 
Interestingly, for the majority of the rBAT mutations observed, the structural 
analysis suggests that the mutations may have an effect on the structure or 
stability of the protein. These mutations fall into two main groups. In the first 
group, a hydrophobic amino acid is replaced by a polar or charged amino acid 
(p.Tyr151Cys, p.Leu205Ser, p.Tyr397Cys, p.Tyr461His, p.Met467Thr, 
p.Tyr579Asp, p.Phe599Ser) where the hydrophobic side chain is typically buried 
and packed against other hydrophobic side chains (Figure 3). In the second 
group, a polar or charged amino acid is replaced by a hydrophobic side chain 
(p.Thr189Met, p.Thr216Met, p.Arg452Trp, p.Ser547Leu) and modelling 
suggests that these mutations remove polar contacts that stabilise the protein 
structure. These four positions are highly conserved in homologous proteins 
indicating an important structural or functional role. Two mutations 
(p.Leu256Phe, p.Thr471Arg) that may affect the stability/packing of the protein 
do not fit into these two groups. For p.Leu256Phe, the increase in size of the side 
chain is likely to alter the side chain packing in this area and for p.Thr471Arg 
there is an increase in both charge and size and this side chain is packed against 
an adjacent beta sheet. 
 
Four other mutations are located close to “functional” regions of the protein. 
p.Gly140Arg is present within the loop where calcium is modelled to be bound 
(Figure 3). This position is completely invariant in homologues suggesting an 
important structural/functional role for this residue. Introduction of a positively 
charged arginine may be expected to interfere with the binding of the positively 
charged calcium ion. p.Thr189Met is located in the alpha helix adjacent to the 
calcium binding site so it is possible that destabilisation here could affect the 
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calcium binding site (Figure 3). Two of the mutations (p.Met381Thr, 
p.Tyr397Cys) are close to what would be the active site if the protein was an 
active hydrolase. p.Met381 is highly conserved in orthologues and the mutation 
to threonine could introduce a polar contact with p.Asp369. For p.Tyr397Cys the 
mutation is likely to remove a polar contact.  
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6.3.2 The b(0+)AT protein (SLC7A9 mutations) 
 
The functional residues identified in SLC7A9 for amino acid binding are: I38, 
I43, S46, G47, W230, A231, Y232, T91, K92, E96, L117, K121, S124, I128, 
I371, L374, V375, F378. Other functional residues are G41, I44, K184 and S312, 
which are likely to be important for transport. As the mechanism of transport is 
not clearly understood there are likely to be further residues that are functionally 
important that have not been identified here.  
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Figure 6.2 Example mutations in rBAT. In all figures the residues that are mutated are red 
in stick format with the wild type side chain. A) mutations close to predicted functional 
residues that bind calcium (Calcium binding residues are light blue). B) A mutation altering 
polar contacts, p.Ser547 makes polar contacts with multiple residues (dark blue), polar 
contacts indicated in purple. Mutation to leucine would remove these polar contacts. C) 
Mutations that introduce polar or charge side chains in hydrophobic regions. In the bottom 
image hydrophobic residues that contact the residues that are mutated are shown as beige 
spheres. p.Arg584 an arginine close to p.Thr471 is coloured blue. 
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Finally, the structural model does not include p.Leu678Pro; this position is 
highly variable in homologues and there is little information to suggest how the 
mutation may alter the protein structure or function.  
 132 
 Figure 6.3 Model of b(0+)AT, Residues modelled to contact the transported amino acids are light 
blue. The conserved p.Lys184 is purple and the conserved residues coordinating with it yellow
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Some of the 15 different missense mutations present in SLC7A9 have been previously 
identified and for some of them experimental studies have suggested how they alter 
protein function101. Overall, we found that mutations in SLC7A9 are primarily either 
close to functional binding sites or close to the end of transmembrane helices. 
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Figure 6.4 Example mutations in b(0+)AT. In all images the mutated residues are displayed as 
red sticks in their wild type format. Predicted functional residues are coloured light blue. A). The 
mutation p.Gly105Arg would introduce a larger  and charged side chain that is close that may 
reduce accessibility for amino acids to enter the transporter. B). p.Ile187Phe and p.Ala182Thr 
mutations are adjacent to p.Lys184 which is thought to play a role equivalent to sodium in 
sodium dependent transporters. C). Mutations close to the end of transmembrane helices may 
reduce stability in the membrane. 
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6.3.3 Genotype-phenotype analysis 
 
The commonest missense mutation in SLC3A1 is p.Met467Thr with a frequency of 
25% (22/88). The most common missense mutation in SLC7A9 is p.Gly105Arg with 
a frequency of 13% (7/55).  
 
The levels of dibasic amino acids associated with each mutation in SLC7A9 are seen 
below.  
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Figure 6.5 The urinary phenotype for each mutation in SLC7A9. The x-axis refers to the levels of 
dibasic amino acids (umol/mmol Cr). The y-axis represents the first mutation. The dot represents 
the second mutation. The second mutation is colour coded based on whether it is non-missense, 
missense, homozygous or wild type. 
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The range of urinary phenotype for each mutation is varied; compound heterozygous 
patients who share one mutation can present with a range of urinary phenotypes. 
From our severity scoring classification in SLC7A9, 11 patients scored 4 and nine 
patients scored 3. Two heterozygous patients with only one mutation scored 2, and 
one heterozygous patient scored 1. When comparing the urinary dibasic amino acid 
levels between compound heterozygous patients with a higher severity score (S=4) 
versus a lower score (S=3), patients with a higher score had higher levels of dibasic 
amino acids. This was statistically significant for arginine (383 umol/mmol Cr IQR 
283 to 392.7 vs 70 umol/mmol Cr IQR 36.38 to 237.3, p=0.0151) and ornithine 
(120.2 umol/mmol Cr IQR 97.67 to 153.1 vs 94 umol/mmol Cr IQR 68.38 to 111, 
p=0.0482), but not cystine (201 umol/mmol Cr IQR 161 to 231 vs 154 umol/mmol Cr 
IQR 133.7 to 191.3, p=0.2545) or lysine (629.5 umol/mmol Cr IQR 593.2 to 814.6 vs 
569.5 umol/mmol Cr IQR 403.6 to 807.5, p=0.2887)115.  
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Figure 6.6 Comparison of urinary phenotype of patients with a severity score of 3 and 4. Group 
1&2 (yellow) represent heterozygotes with only one mutation. There were only 3 patients in this 
group therefore statistical analysis was not possible.  
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Patients with a higher severity score had a higher number of stone episodes (0.5000 
IQR 0 to 1.000 vs 0.0 IQR 0 to 0.2500, p=0.0451) and showed a tendency towards a 
younger age of disease presentation (15.5 IQR 14 to 32.5 vs 29 IQR 14 to 40.5, 
p=0.2081), and more interventions per year (0.6250 IQR 0 to 1.125 vs 0.1250 IQR 0 
to 0.5000, p=0.1569) although these differences was not statistically significant. 
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Figure 6.7 Comparison of clinical phenotype of patients with a severity score of 3 and 4. There 
were only 3 patients in group 1&2 therefore statistical analysis was not possible. 
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The three heterozygous patients with only a single mutation (S=2) had lower levels of 
all four dibasic amino acids (cystine 112.3 IQR 23.67 to 142, lysine 356.7 IQR 127.7 
to 434, arginine 9.833 IQR 2.167 to 11 and ornithine 38 IQR 4.167 to 50.43) than all 
compound heterozygotes.  
 
6.4 Discussion 
Genetic testing revealed a total of 56 different pathogenic mutations in our UK 
cohort, the majority of which are missense mutations. Whilst frameshift, nonsense, 
splice site, deletions and duplications cause large genomic alterations and therefore 
lead to protein dysfunction, it is unclear how missense mutations may affect protein 
structure and function and play a role in disease.  
 
Using structural models to investigate SLC3A1 mutations is more complicated than 
for SLC7A9 mutations because the function of rBAT is not clearly understood. 
Interestingly in rBAT, few mutations directly affected the predicted functional 
residues that would be associated with the enzyme activity that is typically present in 
this family of proteins. However, a large number of mutations introduce a charge into 
a buried region or hydrophobic region and could therefore disrupt protein folding or 
reduce stability. This is consistent with what we know of the rBAT protein; 
experimental studies suggest that the heavy rBAT subunit is essential for cell surface 
expression of b(0+)AT 14 and essential for transport of the heterodimer to the plasma 
membrane. There is evidence to suggest that the extracellular glycosidase domain has 
a role in cystine transport but not the other dibasic amino acids 116. rBAT also requires 
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chaperones to fold correctly and a number of mutations have been linked with 
incorrect folding of the protein and/or trafficking to the plasma membrane 117. The 
interaction between proteins invivo cannot with existing protein models be fully 
appreciated. 
 
rBAT contains an alpha-amylase domain. These domains typically function as 
enzymes that breakdown large linked polysaccharides (e.g. starch) into simple sugars 
such as (glucose). It is not clear if the alpha amylase domain in rBAT performs this 
function and how this may relate to the function of amino acid transport. The presence 
of few mutations close to the functional region of this domain agree with observations 
that this domain is not functionally active. 
 
It is known from prior experimental studies that the light chain b(0+)AT encoded by 
SLC7A9 forms the exchanger of dibasic amino acids for neutral amino 
acids104,105,118,119. It has also been suggested that the light subunit may be fully 
functional even in the absence of the heavy subunit in transfected HeLa cells120. There 
appear to be two main ways in which mutations may affect this light chain subunit 
protein. Multiple mutations are observed close to functional sites in the protein and it 
appears that even conservative mutations (i.e. change to amino acids with similar 
properties) in these regions are sufficient to alter b(0+)AT function. A number of 
other mutations possibly alter the stability of the protein in the membrane.  
 
Whilst many mutations are present in the study, only a few are present in multiple 
individuals. For SLC3A1, only two of the missense mutations are present in two or 
 
 
 
143 
more patients (p.Ser547Leu and p.Met467Thr). Given this limited data, it is not 
possible to draw conclusions on any individual mutation alone. 
 
We observed from our prior study that in patients with mutations in SLC3A1, the 
presence of at least one missense mutation corresponded with patients having 
significantly lower levels of lysine, arginine and ornithine but not cystine than 
patients with all other types of mutations 94. Our data suggests that the presence of a 
missense mutation is likely to result in a less severe phenotype than all other 
combinations of mutations.  
 
An alternative approach was adopted for SLC7A9 using the structural model and 
existing experimental data to assess the level of effect each mutation is likely to have 
on protein function. Each mutation was assigned a score of 1 = low/low-medium 
effect and 2= high/high-medium effect. All non-missense mutations were assigned a 
score of 2 in keeping with our assumptions that these mutations cause large genomic 
rearrangements and consequently protein dysfunction. The missense mutations were 
scored from our modelling predictions. The score was determined by an investigator 
blinded to the clinical data and based on several factors including the proximity of the 
mutation to the predicted functional sites and size of conformational change. Where 
patients had two mutations, the overall severity score was calculated as the sum of the 
score of each individual mutation.  
 
As there were only three heterozygous patients with a severity score of 2, they were 
omitted form the analysis. All three heterozygous patients had lower levels of dibasic 
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amino acids than compound heterozygotes in keeping with other studies10. 
Interestingly, in compound heterozygotes, patients with a higher severity score (S=4) 
had higher levels of urinary dibasic amino acids compared to patients with a lower 
severity score (S=3). This was statistically significant for arginine and ornithine but 
not for cystine and lysine. This finding suggests that protein modelling may help 
predict a patient’s urinary phenotype. The lack of statistical significance for cystine 
and lysine may reflect the limitations of cystine measurement4 and the unique 
transport mechanisms for lysine 75, compounded by a small sample population. 
However, we recognise that the findings may also simply indicate a lack of statistical 
association and more work is needed to explore our hypothesis. Patients with a higher 
severity score had more stone episodes per year and showed a tendency to present 
earlier with disease and had more interventions per year, although the difference was 
not statistically significant for the latter two.  
 
One of the limitations of performing any research in cystinuria is the lack of validated 
measures of disease severity. Any clinical intervention including dietary or medical 
therapy can potentially affect the natural progression of the disease. Collaborations 
with other National and International groups can help to establish a standardised 
measurement of clinical severity to enable further research on genotype-phenotype 
associations 84,85. Clearly, a patient’s genotype can only determine part of the patient’s 
disease profile and clinical phenotype may also be influenced by modifier genes, 
anatomical factors and complex genetic and environmental interactions. An 
equivalent analysis of SLC3A1 was attempted but given the lack of understanding of 
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the function of rBAT, it was not possible to confidently assign many of the mutations 
to a score. 
 
The protein model is generated using a related protein as a template. i.e. the two 
protein sequences are related and one of them has a solved structure. In this case, the 
sequence encoded by p.Leu678Pro is not present in the template protein and therefore 
not modelled. This is the same for p.Ser15Leu and p.Pro482Leu, present at the N and 
C termini respectively in b(0+)AT. The model has also not offered any suggestions as 
to how some mutations can affect protein function. p.Val40Val is a synonymous 
single point mutation resulting in the translation of the same amino acid (i.e. val to 
val). Our protein model does not suggest how silent mutations affects protein function 
although splicing prediction programs suggest that p.Val40Val affects splicing. This 
phenomenon is noted in studies of other diseases also 121. Patients with these 
mutations have not been included in the analysis and their true effect on protein 
function should ideally be experimentally verified.  
 
The advantage of protein modelling is that obtaining experimental data can be time 
consuming, particularly given the number of different mutations in Cystinuria. 
Prospective evaluation is required to assess whether it is possible that the 
classification we have proposed can suggest an indication of severity of an 
individual’s disease.  
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6.5 Conclusion 
Protein modelling has given us insight into how the different missense mutations may 
cause the range of phenotypes seen in cystinuria. Patients with a high severity score as 
predicted by our protein model of b(0+)AT appear to have higher levels of urinary 
arginine and ornithine and more stone episodes than those with a lower score. This is 
a step closer to a personalised approach to the management of patients with 
cystinuria.  
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7 Conclusion 
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7.1 Summary of Results 
There is a wide variation in the phenotype of patients with Cystinuria, this can make 
the management of this rare disease difficult to predict and monitor. My research was 
aimed at exploring potential clinical markers of disease activity and understanding the 
genetic mutations that cause this disease. 
 
7.1.1 The Role of Urinary dibasic amino acids 
 
Cystinuria results in an accumulation of urinary cystine and the urinary dibasic amino 
acids lysine, arginine and ornithine. The levels of urinary cystine have not been 
shown to accurately reflect stone disease or disease severity. Several studies have 
described the inherent limitations of cystine measurement64. We evaluated the utility 
of the other urinary dibasic amino acids in predicting stone formation. We found there 
were higher levels of urinary cystine, lysine and arginine in stone formers compared 
to non-stone formers although the differences were not statistically significant. Only 
urinary ornithine appeared to be associated with stone formation (p<0.05). If urinary 
ornithine can predict whether a patient is likely to form stones, this may be useful in 
the initial assessment of a patient with cystinuria. However, we recognise the 
limitations in its use for monitoring disease activity as most drugs used in the 
management of this disease aim to affect the levels of urinary cystine and do not as 
far as we know have any effect on the other dibasic amino acids. The use of the other 
dibasic amino acid however may be useful in the future if protein targeted therapies 
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are developed. This was the first time that the prognostic value of the non-cystine 
urinary dibasic amino acids has been investigated.  
 
7.1.2 The Role of Urinary crystals 
 
Our next step was to look at the association between the presence of urinary crystals 
and stone formation. We compared EMU and CU samples in patients with stone 
disease and new stone formation and two methods of counting crystals. We found a 
better association between CU and stone disease compared with EMU. Furthermore, 
we found that CU samples analysed by conventional cytospin had the highest AUC 
compared to CU samples analysed by Malassez and EMU samples analysed by both 
methods. This is because large aggregates of crystals are often underestimated by the 
Malassez counting chamber method. In this study, we were not able to replicate the 
solubilisation of cystine crystals following the method described by Dolin et al.  
 
Whilst crystalluria alone is not robust enough as a single diagnostic tests, we propose 
that crystalluria may be useful when used in conjunction with other tests i.e. urinary 
dibasic amino acids, much like the use of PSA in a prostate cancer nomogram.  
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7.1.3 Genetics of Cystinuria in a UK population 
 
No genotype-phenotype correlation has previously been demonstrated in literature 
when comparisons of patients with mutations in SCL3A1 and SLC7A9 have been 
made10.  
 
This was the first study of a UK cystinuria population and we found our cohort to be 
genetically diverse with 57 mutations of which 23 were not previously described. The 
majority of mutations in our cohort were missense mutations. We compared patients 
with at least one missense mutation in SLC3A1 with patients with combinations of all 
other mutations. We hypothesized that missense mutations would cause less protein 
dysfunction than all other mutations. We found that patients with at least one 
missense mutation had lower levels of the urinary dibasic amino acids. This was 
statistically significant for urinary lysine, arginine and ornithine but not cystine. This 
demonstrated for the first time that a patient’s genotype can determine urinary 
phenotype. The lack of a statistically significant relationship for urinary cystine may 
be due to the limitations in cystine measurement as previously described64.  
 
We examined the correlation between genotype and clinical phenotype using our 
classification. Although we found that patients who had at least one missense 
mutation were less likely to form stones and require fewer interventions, this 
association was not statistically significant. There were however some recognised 
limitations to how the data was collected and recorded that may account for this. For 
our study, we defined a stone episode as any episode of stone that has been reported 
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by a patient including those passed spontaneously, those causing colic and stones that 
require intervention over a four-year period. We found that patient recall of their 
stone episodes was often unreliable. Furthermore, one can argue that this method of 
reporting is too simplistic as not all stones are the same. Stone burden can vary and a 
stone requiring PCNL may arguably have greater ‘weight’ than one that can be treated 
ureteroscopically.  Likewise, a stone requiring intervention has greater ‘weight’ than a 
stone that can pass spontaneously. Therefore, it is fundamental that in order for 
further research into this disease to continue, a more standard instrument for 
evaluating clinical disease severity must be established. 
 
Furthermore, some patients were followed up more frequently than others. The factors 
that influence this included the patient’s initial presentation and stone burden, 
frequency of stone episodes, whether they were on any medications that required 
monitoring, and renal function. Cystinuria affects predominantly a young working 
population and clinicians must balance the frequency of clinic visits to the disruption 
to patient’s lives. These were all considerations we recognise as limitations to 
conducting research in an opportunistic environment and may account for the lack of 
statistical association in some of our results. 
 
It was not possible to apply this genetic classification to evaluate patients with 
SLC7A9 mutations. Firstly, all patients with SLC7A9 mutations except one had at 
least one missense mutation therefore making statistical comparisons impossible. 
Secondly, the inheritance pattern for patients with SLC7A9 is less well defined; 
patients can have one mutated allele and present with cystine stones. 
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The results of this study on one of the largest population of patients with cystinuria 
show for the first time a genotype-phenotype association that is applicable to patients 
with mutations in SLC3A1. Patients with at least missense mutations have a 
biochemically less severe phenotype as evidenced by lower levels of urinary lysine, 
arginine and ornithine. This potentially has a role at initial diagnosis at determining 
frequency of follow up. 
7.1.4 The Role of Protein Modelling 
 
Due to the limitations of our classification described above, a different approach was 
adopted for examining SLC7A9 mutations. We applied a validated protein modelling 
software to determine the effect mutations would have on the end-protein. We found 
we were able to determine the location of mutations in relation to the ligand-binding 
sites and the degree of conformational change. We used this model to classify our 
mutations in SLC7A9 into those that were predicted to cause a high effect (S=2) and 
those predicted to cause a low effect (S=1). Patients with heterozygous mutations 
were then given an overall score; a sum of the individual scores of each mutated 
allele.  
 
We found that patients with a score of 4 had higher levels of urinary arginine and 
ornithine than patients with a score of 3. Patients with a higher score also had more 
stone episodes.  
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This finding demonstrated that protein modelling may partly help us to understand the 
genetic mutations identified in our UK cohort. It is uncertain the role of protein 
modelling in examining mutations in SLC3A1 as the role of the rBAT protein is less 
clearly understood. Experimental studies are time-consuming and the results would 
lag significantly behind the rate at which new mutations are being reported. Using 
protein modelling, we can suggest how individual mutations can lead to protein 
dysfunction. This is the first step towards a personalised approach to the management 
of patients with this disease.  
 
7.2 Implications for Current Practice 
 
Patients with cystinuria are clinically and genetically diverse. Given the wide range of 
presentations, patients need a tailored approach to the management of their disease. 
Currently, a method of determining a patient’s disease severity is lacking, and only 
following a period of observation can we determine whether someone has ‘mild’ or 
‘severe’ disease.  
 
There are currently no clinical markers to help us monitor patients with cystinuria. 
Measurement of urinary cystine is flawed as it exists in both soluble and insoluble 
form. Our study findings demonstrate that urinary ornithine may have some use in the 
initial assessment of a patient but currently lacks value in the monitoring of patients 
particularly if they are on thiol-binding medication.  
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Prior studies suggested that early morning urine is the most accurate assessment of 
urinary cystine due to the overnight saturation of the cystine. However, we have 
found that clinic urine is better associated than early morning urine for stone disease. 
Again, clinic urine is strongly associated with stone disease but on its own, it is not 
robust enough to be of diagnostic or prognostic use. It may be possible to use this 
association in conjunction with other tests as a marker for predicting a patient’s 
disease severity.  
 
With regards to genetics, for the first time we can use a patient’s genotype to make 
suggestions on urinary and clinical phenotype. We may be able to use this 
information to tailor a patient’s management and determine the frequency of clinic 
visit. Clearly, a patient’s genotype can only determine one aspect of a patient’s 
disease and there are currently unknown epigenetic and environmental factors that 
would influence a patient’s clinical course. By understanding how individual 
mutations can affect protein function, this has led to greater insight into this disease 
and provide a model whereby protein targeted therapies can be tested.  
 
7.3 Future Challenges  
 
My research has provided a better understanding on the utility of the cystine and the 
other dibasic amino acids in predicting severity of cystinuria. Urinary ornithine 
appears to be associated with stone formation and can act as a proxy for disease 
severity. However, its usefulness is hampered as current treatments in cystinuria aims 
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to reduce cystine levels only and as far as we know, does not affect ornithine levels. 
We have also found that the levels of urinary dibasic amino acids are increased to 
varying degrees. We do not currently understand why some patients have higher 
levels of one dibasic amino acid compared to another and further research into this 
may be useful. For example, further understanding of why individual urinary dibasic 
amino acids levels vary may help to develop a therapy for the selective transport of 
urinary lysine, arginine and ornithine in place of cystine.  
 
We observed whilst doing this work using ion-exchange HPLC to detect the amount 
of cystine in our samples, a penicillamine-cysteine peak can also be detected, eluting 
just after cystine (refer to Figure 3.1). Further research into the ratio of these peak 
complexes may prove to be more useful, particularly in monitoring the effectiveness 
of patients on thiol-binding drugs.  
 
Our genetic study revealed over 50 different mutations in our population, 23 of which 
have not previously been described. We did not find mutations in three patients 
suggesting there may be more genes involved in the disease or complex interactions 
between polymorphisms that we do not completely understand. More recently a new 
transporter in SLC7A13 has been described and performing DNA analysis looking for 
mutations in this gene may help us to understand the handful of patients without a 
mutation in SLC3A1/SLC7A9100. More genome-wide studies are required to look for 
mutations in other genes. Whether or not a better understanding of these genes will 
allow us to develop gene or protein targeted therapies remains to be determined. Our 
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protein model may also allow a platform for which potentially new drugs can be 
tested.  
 
Other groups have described using SLC3A1 and SLC7A9 knockout mice to facilitate 
the development and rigorous evaluation of novel therapies.29,122,123 The mouse model 
has been used in the testing of dimethyl ester (L-CDME), a cystine analogue that 
disrupts cystine crystal formation by attaching to their surfaces. CDME can reduce 
stone mass and size but has not yet been tested in clinical trials124.  
 
Further cystinuria research will require consensus on a validated method of measuring 
disease activity which can be facilitated by collaboration with groups such as the 
National Registry of Rare Kidney Disease (RaDaR)84. Crucially, we need to define 
standards to aid in both research and clinical practice.   
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